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ATOPy
Knowing the atopy status of patients is considered valuable information in derma-
tologic daily clinical practice. As a rule, in all patients presenting with a pruritic or an 
inflammatory skin condition, history of atopy is taken and documented. The importance 
of this information has been recognized and taught to residents for decades. The 
dermatologists know by experience that an atopic predisposition may be a clue to the 
diagnosis or a direct explanation for the patient´s complaints. In epidemiologic terms, 
the dermatologist is assessing for the risk factor ‘atopy’ and including or ruling out its 
comorbidities. Despite its daily use, the exact meaning of the term “atopy” has not been 
precisely delineated and the research into its comorbidities has not been approached 
in a systematic way.
The word “atopy” comes from the Greek word ἀτοπία which literally means “place-
lessness” but was intended to roughly mean “extraordinary” or “unusual”. The term 
was coined by Coca and Cooke in 1923.1 At that time it designated all immunologic 
phenomena which do not contribute to the body defenses against pathogens. Since 
then atopic disorders were thought to represent hypersensitivity reactions i.e. reactions 
of the immune system against harmless antigens. After the discovery of the Immuno-
globulin E (IgE) in 1966 the term atopy was reserved for disorders in which IgE played 
a direct pathophysiological role.2 Patients with atopic disorders, asthma, hay fever and 
atopic dermatitis (AD) were thought to be predisposed to producing IgE against vari-
ous antigens such as house dust mite proteins, cat dandruff and pollen. As this is the 
case with many atopic individuals, some experts argue that the term “atopic” should 
be reserved for the ones exhibiting increased levels of serum IgE. In recognition of the 
heterogeneity of asthma and atopic dermatitis, new nomenclature had been developed 
in order to differentiate between “intrinsic”, without, and “extrinsic”, with increased IgE 
levels variants of these diseases.3 Currently “atopy” has come to mean: a heritable consti-
tution which predisposes individuals to the development of asthma, food allergies, hay 
fever and AD. These four distinct, comorbid conditions are subject to paradigm shifting 
and continually evolving definitions. Currently all four diagnoses are made by meeting 
validated, clinical disease criteria. However, no overall criteria for “atopy ”exist. Besides 
the strongly associated atopic disorders, atopy is also considered to be a risk factor for 
various non-atopic conditions. The main emphasis of this thesis is on the association of 
AD with non-atopic conditions.
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ATOPIC dERMATITIS
Epidemiology
AD is also known as eczema, atopic eczema, Besnier’s prurigo, infantile eczema, flexural 
eczema, neurodermatitis and “constitutioneel eczeem” in Dutch. AD is usually the first 
atopic condition to be seen in an atopic individual and brings the atopic individuals to 
the attention of dermatologists. AD is also the most common inflammatory skin disease 
affecting up to 30% of infants and 10% of adults with its incidence tripling over the past 
three decades.4-6 AD is typically a disease of the infancy as more than 50% of the patients 
develop the disease before the age of 6 months. Up to 70% of all infant cases of AD 
remit by the age of 7.7 Risk factors for the development of AD are a family history of AD 
and other atopic disorders, exposure to bacterial endotoxins during the first year of life, 
exposure to antibiotics and decreased diversity of the gut microbiota. Protective factors 
are day care attendance, exposure to farm animals, consumption of unpasteurized milk 
and exposure to dogs. 8
Pathophysiology
Although the AD pathophysiology is multifactorial and very complex its pathogenetic 
pathways can be roughly categorized in to epidermal barrier defects and aberrations 
of the adaptive immune system.9 In short, the disturbances in the skin barrier lead to 
transepidermal water loss and xerosis but also allow penetration of antigens and toxins 
which then activate other parts of the innate and the adaptive immune system. As a 
consequence, inflammation and even further degradation of the skin barrier follow, 
presenting with classic signs of dermatitis in the skin.
One of the crucial barrier genes implied in the development of AD is the filaggrin gene 
(FLG).10,11 The most common mutations in whites are R501X and 2284del4 and are found 
in 50% of severe and 30% of all AD cases. Some rare mutated variants of this gene in-
crease the odds of AD by 151 fold.12 The FLG codes for a protein called profilaggrin which 
after proteolysis becomes filaggrin and provides molecular scaffolding for the epidermal 
keratinocytes and contributes to the compaction of the stratum corneum and cohesion 
between its constituents.13 Filaggrin cleavage by caspase-14 is required for its proper 
functioning.14 A major derivative of this cleavage process is urocanic acid.15,16 Urocanic 
acid provides protection against dehydration and low-level protection against UVB-
induced DNA-damage.17,18Nevertheless, as only 30% of European patients with atopic 
dermatitis are a carrier of FLG mutations, deficiencies in other epidermal barrier con-
stituents probably play an additional role.19-21 There is evidence that the dysfunctions in 
other components of the epidermal barrier such as the cornified envelope, intercellular 
lipid lamellae, corneodesmosomes and corneocyte desquamation also play a role.22,23 
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1Nevertheless, it was the discovery of the specific role of filaggrin in 2006 that shifted the pathophysiological paradigm to epidermal barrier dysfunction as the initiating step.24 
This sparked a multitude of novel research on filaggrin producing increasing numbers 
of papers. Mutations in the FLG gene are not only a risk factor for severe and persistent 
AD but also increase the risk of asthma by 3 times in the presence of eczema. 25,26 After 
the disruption of the epidermal barrier which is considered a failure of the first line of the 
innate defenses, other innate and adaptive parts of the immune system drive the patho-
physiology. The inflammation involved is orchestrated by the Th2 lymphocytes through 
thymic stromal lymphopoetin (TSLP) and the cytokines IL-4, IL-5, IL-13 and IL-22.27,28 In 
the chronic phase the Th1 and the Th17 axes are also involved.29 There is a buildup of 
evidence of the involvement of the recently discovered lineage of group 2 innate lym-
phoid cells (ILC2s). Just like Th-2 lymphocytes the ILC2s produce large amounts of Th-2 
cytokines, stimulate IgE production and show increased counts in AD, asthma and hay 
fever.30 There is also an important role for microbes. Staphylococci, found in the lesional 
skin of up to 90% of the AD patients are also thought to add to this inflammatory mixture 
by further degrading the barrier by proteolytic enzymes and through the elicitation of 
immune responses by their enterotoxin.31 With the help of the staphylococcal protease, 
the staphylococci penetrate the epidermis leaving a trail of inflammation characterized 
by increased secretion of IL-4, IL-13, IL-22 and TSLP while inhibiting the production of 
Th-1 cytokines and chemokines normally responsible for the coordination of clearance 
of staphylococcal infections.32,33 The presence of staphylococci at least perpetuates the 
inflammation but may also be the major initial cause of AD.34,35
From Ad to a system disease
A serologic marker of atopy in AD is the IgE anti-body. Eight to 80% of patients with AD ex-
hibit increased levels of IgE depending on whether the study was community or hospital 
based.36 Raised IgE correlates positively with AD severity and a worse long term progno-
sis. Though many AD patients may exhibit increased serum IgE levels, the IgE-repertoire 
in AD patients is much more restricted than in patients with asthma or hay fever which is 
suggestive of sensitization by a superantigen.37 Furthermore, autoreactivity to proteins 
homologue to environmental antigens may also play a role.38 Several other potential 
serum markers of AD exist such as thymus and activation regulated chemokine (TARC), 
T-cell attracting chemokine (CTACK), E-selectin, macrophage-derived chemokine(MDC), 
LDH and IL-18.39,40 Recently α-defensin has been found to be increased during flare-ups 
of AD.41 Although all four atopic diseases take stage at the interface between the body 
and the outside world the barrier dysfunction in the skin seems to precede and influ-
ence the onset of asthma, hay fever and food allergy (table 1).
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One of the peculiarities of the atopic constitution is that patients may develop any and 
all of the four atopic disorders while their onset usually takes place in a fixed order. This 
specific and strong serial clustering of comorbidities is called the atopic march.42 In 
practice, the atopic march means that an infant with AD could develop food allergies 
concomitantly and may go on to become asthmatic during childhood and later on dur-
ing adolescence get affected by hay fever (figure 1). Subsequently, the atopic patient 
could present to various specialties with complaints related to any of these conditions. 
In addition, the rising incidence of atopy makes it a significant health problem. Taken the 
foregoing into consideration, atopic disorders make for a very interesting and challeng-
ing field for the study of comorbidities, be it from an epidemiologic or an immunologic 
point of view.
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Figure 1. The course of the atopic march.
Clinical presentation
Patients with AD classically present with itch (pruritus), skin lesions and dry skin. The 
dermatologic findings typically vary with age. In infants AD usually presents with ery-
thema, weeping and serous crusting on the face (figure 2).
On the trunk there may be red edematous papules and vesicles. The flexures of the neck 
and scalp may be involved in infants. During childhood lichenification sets in and lesions 
typical of AD can be found in antecubital and popliteal flexures. In adults more hand 
and periorbital dermatitis can be found. Persistence of AD in adulthood is more likely in 
patients with early onset, hay fever and hand dermatitis during childhood.43 AD is there-
fore a polymorphous cutaneous disease which presents with multiple efflorescences at 
the same time (figure 3)
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Figure 2. Evolution of atopic dermatitis from infant and child to adolescent
Figure 3. Atopic dermatitis of the popliteal fl exures. There a papules, vesicles, lichenifi cation, hemorrhagic 
and serous crusting, excoriations, vaguely demarcated erythema and scaling.
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Table 1. Illustration of the anatomic localization of atopy according to the specific disease
Atopic disease Involved body interface
Atopic dermatitis Skin
Asthma Respiratory lining
Hay fever Conjunctiva and nasal mucosa
Food allergy Oral mucosa, esophageal mucosa, gut lining
The diagnosis is made by symptoms and clinical findings only. The diagnosis of AD is 
usually made according to the diagnostic guidelines for atopic dermatitis by the U.K. 
working party which is the most validated diagnostic tool in the clinical and investiga-
tional settings.44 These criteria comprise one major criterion plus three or more minor 
criteria. ‘An itchy skin condition in past 12 months’ is the must have criterion and the 
participant needs to fulfil at least three minor criteria which are: ‘history of involvement 
of the skin creases’, ‘a personal history of asthma or hay fever’, ‘a history of generally dry 
skin in the last year’, ‘visible flexural eczema’ and ‘onset under 2 years of age’ (table 2)
Table 2. UK working party’s AD criteria
Major Itchy skin condition past 12 months
Minor Personal or 1st degree relative history of asthma or hay fever
History of involvement of skin creases
History of generally dry skin
Visible flexural dermatitis
Onset below age of 2
The major criterion is obligatory and the patient must fulfil at least 3 minor criteria.
Treatment
The treatment of AD consist of two pillars: restoration of the epidermal barrier and halt-
ing of the inflammatory reaction.45 The first is achieved by avoidance of barrier damag-
ing agents such as excessive use of soaps and water and applying generous quantities 
of emollients. Irritants such as wool, sweating and chlorine should also be avoided.46 The 
second part is achieved with topical corticosteroids in most cases.47 Application of these 
medications quickly reduces the pruritus and the inflammation and helps to restore and 
maintain the skin barrier at a very low risks of adverse events. In the past two decades 
topical calcineurin inhibitors have found their way in to the dermatologic arsenal for AD 
and prove to be a good alternative in some AD cases.48 Another emerging topical treat-
ment with good effect are inhibitors of phosphodiesterase-4.49 However in the topical 
class the corticosteroids remain unchallenged in terms of efficacy, adverse events pro-
file and cost effectiveness. Unfortunately in moderate and severe cases of AD, topical 
treatment only may not be sufficient. Treatment with UVB is then usually successful but 
15
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1cannot be continued indefinitely.
50 Short or long courses of oral corticosteroids can be 
considered with or without the addition of azathioprine.51 Other immunosuppressants 
which have been shown to be effective are ciclosporin A, mycophenolate mofetil and 
methotrexate.52-54 Dupilumab, a monoclonal antibody that blocks IL-4 and IL-13 has 
shown very promising results but is as of now not registered in the Netherlands.55,56 
More biologic treatments are expected to be developed in the near future. Besides 
pharmacologic treatment, counseling, patient education and even psychologic care are 
often necessary.57
ATOPIC dIATHESIS ANd COMORBIdITIES
Background
Comorbidity is the co-occurrence of two or multiple diseases in one patient. It is associ-
ated with worse clinical outcomes, increased health costs and more complex clinical 
management. 58 The construct of comorbidity is used differently in the fields of clinical 
care and public health. In the clinical sense a comorbid disease may or may not share 
the same pathogenesis or may even be a “complication” of the index disease. The co-
morbidities may or may not associate more frequently than is expected on the basis of 
chance. When this is the case however, there is an association or sharing of risk factors. 
Research into comorbidities provides valuable knowledge of the etiological models of 
disease as well as potential prevention approaches. The emphasis of this thesis is on AD. 
Dermatologic research on this topic however, cannot be conducted without accounting 
for the highly associated asthma, hay fever and food allergies which are all part of the 
atopic diathesis.
Atopic diathesis: asthma, hay fever and food allergies
Asthma is a chronic inflammatory disease of the lower respiratory tract caused by in-
flammation and remodeling of the airways. The inflammation is Th2 driven and IL-4 and 
IL-13 play the primary roles.59,60 Asthma usually presents with coughing, wheezing and 
shortness of breath and is characterized by expiratory flow restriction due to bronchial 
hyperresponsiveness. The symptoms can be triggered by non-specific stimuli such as 
smoke and cold but reactions and sensitization to aeroallergens are found frequently.61 
The incidence is rising and 75% of the patients develop their asthma before the age 
of 7.62 Having had AD as an infant increases the risk of developing asthma by two-fold 
(table 3).42 About 40% of children with AD with IgE-sensitization will develop asthma.63,64 
Patients with early onset AD, multiple sensitizations and familial history of asthma are at 
highest risk of developing asthma.65,66
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Table 3. Odds ratios and chances of asthma, hayfever and food allergies in atopic dermatitis
Atopic disorder Fold increase of chance in Ad Chance in Ad
Asthma 2 Mild AD: 20%
Severe AD: 60%
Hayfever 2 50%
Food allergies 3-6 Mild AD: 5%
Severe AD: 30%
Hay fever consist of the syndromes of allergic rhinitis and allergic conjunctivitis and pres-
ents with itchy, red eyes, sneezing and nasal congestion. Its prevalence is approximated 
between 10 and 30% in the industrialized countries.67 Roughly 50% of children with AD 
develop hay fever.63 Sensitization to common allergens can be identified through serum 
IgE testing or skin prick tests. However, the diagnosis can be made on the basis of clinical 
findings only.
Cumulative incidence of food allergy is around 5% by the age of 2 years.68 IgE-mediated 
food allergies typically present with urticarial, oral and gastrointestinal symptoms, dys-
pnea and wheezing and anaphylaxis. Although late-onset reactions have been reported 
aggravation of AD by food allergies is debatable.69 Allergies to cow’s milk, hen’s egg and 
wheat usually resolve after infancy but those to peanuts and fish typical persist and exhibit 
more severe symptoms.69 Sensitization to food allergens can be found in up to two thirds 
of infants with moderate to severe AD and food allergies can be found in up to 30% of 
severe infant cases of AD.70 The prevalence in mild cases and in adults is much lower.71,72
Non-atopic comorbidities
The association between atopic disorders as a group has been known for many years. 
Therefore, atopy is considered a spectrum of diseases or a diathesis. More recently, as-
sociations with other, non-atopic diseases are increasingly recognized. Atopic disorders 
have been linked to a number of Mendelian inherited disorders. These are ichtyosis vul-
garis, Netherton’s syndrome, Job’s syndrome, DiGeorge syndrome, Nezelof syndrome, 
selective IgA deficiency, Wiskott-Aldrich syndrome, peeling skin syndrome type B and 
skin dermatitis-multiple severe allergies-metabolic wasting syndrome .73 Studying these 
comorbidities has provided insight into the pathophysiology of atopic disorders.74
However, the list of co-morbidities not associated with single gene mutations is even longer.
Every year new comorbidities are added to it, some of which are considered to be truly a 
part of the atopic constitution. This is the case with eosinophilic esophagitis for example. 
The studies which have specifically and directly assessed the association between AD 
17
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1and a possible comorbidity are listed in (Table 4). It is worth noting that the inflamma-tory and infectious disorders mainly colocalize in the skin.
Table 4. Non-atopic comorbidities associated with atopic dermatitis and atopy in general
Atopic condition Comorbidity Highest level of evidence 
studies
Atopic dermatitis Inflammatory
Alopecia areata Meta-analysis70
Vitiligo Meta-analysis70
Lichen sclerosus Case-control71
Atopic eruption of pregnancy Case series72
Infectious
Eczema herpeticum Case series73
Verruca vulgaris Cohort74
Molluscum contagiosum Review75
Impetigo Case-control76
Upper and lower airway infections
Gianotti-Crosti syndrome
Cohort74
Case-control77,78
Neoplastic
Skin cancer Cohort 79-81
Lymphoma
Psychiatric
Systematic review82
Attention deficit hyperactivity disorder Meta-analysis83
Depression Cohort84
Autism Systematic review85
Cardio vascular
Obesity Meta-analysis86
Hypertension Cohort87
Myocardial infarction Cohort87
Stroke Cohort88
General atopy Inflammatory
Keratoconus Case control89
Retinal detachment Cohort90
Eosinophilic esophagitis Review91
Cataract Case series92
Glaucoma Case series93
Infectious
HIV
Respiratory viral infections
Neoplastic
Review94
Meta-analysis95
Keloid Case series96
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Possible biologic pathways in comorbid disease
Several of biologic mechanisms could explain how impediments on the molecular level 
in AD possibly contribute to the comorbidities found in epidemiologic studies. First, 
the defective epidermal barrier allows penetration by damaging agents such as toxins, 
radiation and microorganisms. This obviously predisposes to infections and inflamma-
tory disorders. Second, the Th-2 polarized immune system fails to address intracellular 
pathogens leading to infections.102 There is further an increased turnover of epithelial 
and hematopoietic cells which could lead to mutations and consequently cancer. The 
continuous state of inflammation may also reflect on the cardiovascular system through 
increased circulating levels of pro-inflammatory molecules i.e. systemic inflammation. 
This is illustrated in (Figure 4).
Th-2
Impaired Epidermal Barrier Immune System Alterations
Decreased protection against pathogens
• Infections: bacterial; fungal; viral
• Skin cancer
Decreased protection against UV-light
• Skin premalignancies
• Skin cancer
Downregulation of the innate immune system
• Infections: bacterial; fungal; viral
Th-2 polarization
• Systemic inflammation: cardiovascular disease
• Increased cellular turnover: cancer
Figure 4. Hypothetical comorbidity pathways in atopic dermatitis
Anti-morbidities
Aside from the research performed in the field of the comorbidities of atopy almost equal 
attention has been given to the phenomenon of the decreased risk of auto-immune 
and auto-inflammatory disorders in atopic individuals.103 Various epidemiologic studies 
have shown a reduced prevalence of atopic disorders in type 1 diabetes and rheumatoid 
arthritis (RA).104-112 There is also some evidence for this phenomenon in multiple sclero-
sis.113,114 The conceptual framework for these findings has traditionally been provided by 
the paradigm of the T-helper subsets and their mutual antagonism (figure 5).
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Figure 5. T-helper lymphocyte subsets and their functions.
The known types of inflammation are categorized according to the main T-helper cell 
subset involved. From vast quantities of research it is clear that during certain phases of 
inflammation, specific T-helper cells and their cytokines predominate in affected tissues. 
However, the Th-cells seem to be able to switch roles and to relinquish their dominance. 
This is seen in the chronic phases of AD and asthma where Th-17 cells take over from 
Th-2 cells. Moreover, two different lineages can be at work at the same time as Th-1 
and Th-17 axes seem to play an equal role in rheumatoid arthritis. It is therefore not 
possible to categorize all inflammatory disorders in static divisions such as presented in 
figure 3 which is an illustration of a heuristic approach. In this figure the novel discovery 
of Th-22 and Th-9 cells has been left out as their pleiotropical functions have not yet 
been fully characterized.115-118 To complicate matters even more, there is in vivo and in 
vitro evidence that the Th-cell subsets antagonize each other’s functions. Th1/Th17 and 
Th2 types of inflammation control exhibit opposing immunologic mechanisms and the 
signature cytokines of Th-1 cells can make the Th-2 cells switch class.119-121 On the other 
hand IL-4 ameliorates the inflammatory effects of Th-1 cells while IFN-γ and IL-4 inhibit 
Th-17 differentiation.122 Summarizing, some auto-inflammatory and auto-immune dis-
orders may be either precluded or attenuated by Th-2 polarized atopy. This leads to the 
inverse associations between these disorders and atopy. They could be perceived as 
contraries of comorbidities: anti-morbidities.
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AIMS OF THIS THESIS
The main objective of this thesis was to explore and assess the associations of non-
atopic comorbidities with atopic disorders and how atopy influences the course and/or 
severity of these conditions. The comorbidities are divided into inflammatory, cancerous 
and cardiovascular disorders. The chapters of this thesis correspond to this division.
In the first part of the second chapter we have assessed for associations between atopy 
and psoriasis vulgaris and psoriatic arthritis. Psoriasis vulgaris is a prevalent inflamma-
tory skin disease which has psoriatic arthritis as its commonest comorbidity. They share 
the immunopathogenetic pathways which are mainly Th-17 oriented. A possible positive 
association with atopy would be of great interest as psoriasis vulgaris is also thought to 
stem from epidermal barrier dysfunction. A negative association could be expected as 
well because of a possible Th2-Th17 antagonism. In the second part of chapter 2 we 
describe the abnormalities seen within B-cells of patients with atopic dermatitis. The 
research on inflammatory skin disorders and particularly the research on AD has mainly 
focused on the T-lymphocytes. With IgE being the hall mark of atopy looking into the 
immunoglobulin producing B cells cannot be omitted.
The first part of chapter 3 summarizes the evidence for the role of the epidermal barrier 
in the protection against UV-light induced cancers. Damage to this barrier could make 
humans more susceptible to keratinocyte cancers. The second part goes deeper into the 
association of skin cancer in AD in community dwelling patients. The third part assesses 
the association between melanoma and AD. With melanoma having the highest mor-
bidity and mortality rates this was an obvious target for our research. The fundamental 
motive for this research are the phenomena of a damaged barrier (decrease in innate 
immunity) and Th-2 skewing (decreased tumor clearance by the Th-1 axis) which could 
lead to increased incidence of skin cancer in atopic individuals.
In chapter 4 we have focused on the association between AD and cardiovascular disease 
(CVD) and cardiovascular risk factors. CVDs are increasingly the subject of dermatologic 
studies. Our study was done within the Rotterdam Study as this cohort was designed to 
deliver high quality, validated data on cardiovascular disease.
Chapter 5 is the general discussion commenting on the findings, the methodologies 
and their limitations and putting them in a broader scientific and clinical context.
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ABSTRACT
Background: The prevalence of atopic disorders is reduced in patients with various au-
toinflammatory diseases, but this association has not been studied in psoriasis vulgaris 
or psoriatic arthritis.
Objective: To compare the prevalence of hayfever, asthma and sensitization to common 
aeroallergens in patients with psoriasis vulgaris and patients with psoriatic arthritis to 
controls and to investigate whether atopy influences the arthritis activity and severity 
scores in psoriatic arthritis patients.
Methods: In a cross-sectional cohort study design, the differences in patient-reported 
lifetime prevalence of atopic disorders and serum immunoglobulin E directed against 
common aeroallergens were compared. The effect of atopy on arthritis severity was 
assessed using the Disease Activity Score 28 and Health Assessment Questionnaire. 
Logistic regression models were used to calculate crude and adjusted odds ratios with 
95%-confidence intervals for presence of atopy.
Results: One hundred and sixty-eight patients with psoriatic arthritis, 133 psoriasis 
vulgaris patients and 147 controls were included. The life time prevalence of hayfever 
did not differ across groups. Patients with psoriatic arthritis were less likely to have suf-
fered from asthma than controls; adjusted OR=0.20 [CI 95% 0.04-0.92] and they were 
less likely to be sensitized; adjusted OR=0.50 [95%CI 0.25-0.99]. HAQ-VAS for pain and 
HAQ-VAS for patient global score were significantly reduced by sensitization to common 
aeroallergens (beta-coefficient -0.54 [95% CI -0.84 - -0.25] and -18.4 [95% CI -28.5 - -8.25] 
respectively.)
Limitations : This is a cross-sectional, small numbered study.
Conclusion: Atopy may protect against development of psoriatic arthritis and diminish 
its severity.
Key words
Atopy, asthma, hayfever, psoriatic arthritis, psoriasis vulgaris, life-time prevalence
Capsule summary
The prevalence of atopic disorders is diminished in rheumatoid arthritis.
The prevalence of atopic disorders is also diminished in patients with psoriatic arthritis.
Atopy may be a risk determinant and a severity predictor for psoriatic arthritis.
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ABBREvIATIONS
PSO   psoriasis vulgaris or chronic plaque type psoriasis
PSA   psoriatic arthritis
OR   odds ratio
RA   rheumatoid arthritis
95% CI   95% confidence interval
Th   T-helper cell
CASPAR   Classification Criteria for Psoriatic Arthritis
PASI   Psoriasis Area and Severity Index
DAS 28   Disease Activity Score 28
HAQDI   Health Assessment Questionaire-Disability Index
HAQ-VAS  Health Assessment Questionnaire Visual Analogue Scale
SD   standard deviation
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INTROdUCTION
Psoriasis vulgaris (PSO) is a common inflammatory skin disorder affecting around 2% of 
the Western population.1 Approximately 11% (the estimates go up to 24%) of PSO pa-
tients also have psoriatic arthritis (PSA)2. It remains controversial whether PSO and PSA 
are part of the same disease process or merely embody a strong association between 
two distinct entities with overlap in genetic susceptibility loci.3 Despite the enormous 
differences in clinical manifestations, the inflammation in both diseases is concerted by 
Th-17 (T-helper) and Th-1 cells.4 While Th-17 and Th-1 cells in cutaneous and arthropatic 
psoriasis may work synergistically to produce the inflammation seen in these disorders, 
type-2 Th-cells have been shown to antagonize the inflammation caused by these cells 
on a cytokine level.5-6
Th-2 cells are important players in inflammation seen in atopic disorders.7
Atopy is a hereditary predisposition to allergic sensitization, i.e. development of IgE 
antibodies directed against various allergens. Clinically, it is a risk factor for the develop-
ment of atopic dermatitis, hayfever and atopic asthma.
There is a multitude of epidemiologic studies which have shown lower prevalences of 
atopic disorders in patients with Th-1 mediated diseases. 8 These observational studies 
have shown that in rheumatoid arthritis (RA), which is a Th-1 driven disease, patients 
have lower prevalences of atopic disorders compared to controls. Moreover, hayfever 
may ameliorate the symptoms of RA.9-11 These data suggest the existence of mutual 
exclusion or antagonism between atopic and autoinflammatory/autoimmune disorders, 
where Th-2 driven atopy protects against Th-1 driven disorders. The association between 
atopic disorders and PSA and the effect of atopy on PSA severity have not been studied 
yet.
The objective of this study was to compare the prevalence of clinical and serological 
manifestations of atopy in patients with PSA to PSO patients and healthy controls. We 
hypothesized that the prevalence of atopic disorders is lower in patients with PSO and 
PSA and that atopic PSA patients have a less severe disease
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PATIENTS ANd METHOdS
Study population
The study subjects were recruited from March of 2009 until February of 2011. The PSA 
patients were recruited from the department of rheumatology at Maxima Medisch 
Centrum in Eindhoven. Patients with PSO and controls were recruited from the depart-
ment of dermatology Erasmus Medical Centre in Rotterdam. All participating patients 
provided written informed consent. PSA diagnosis was confirmed by a certified rheuma-
tologist and all patients fulfilled the CASPAR criteria12. All PSO subjects were diagnosed 
with psoriasis vulgaris by certified dermatologists and had no history or signs of inflam-
matory arthritis. The control group consisted of individuals with varicose veins who 
did not have either PSO or PSA. Only controls who had been referred for phlebological 
consultation by a general practitioner were included in order to avoid inclusion of atopic 
patients with concurrent varicosities referred by dermatologists.
Patient reported atopic disease
Directly after inclusion patients were given a questionnaire comprising questions from 
the European Community Respiratory Health Survey and International Study of Asthma 
and Allergies in Children protocol13-14. This questionnaire provided data on patient’s 
self-reported symptomatology of atopic disorders (i.e. contact dermatitis, hayfever and 
asthma) during their life time. Subjects were considered to have asthma if they positively 
answered the question “Have you ever been diagnosed with asthma by a doctor?” and 
if the answer to question “How old were you when you were diagnosed with asthma?” 
was less than 25 years. For diagnosis of hayfever patients had to answer next question 
affirmatively; “Have you ever had hayfever?” and they would have to have it before the 
age of 30. We have left out atopic dermatitis from further analysis because of the clinical 
similarities with psoriasis vulgaris.
Total IgE levels and sensitization to common aeroallergens
As an objective marker of atopy IgE directed towards common aeroallergens together 
with total serum IgE was preferred to skin prick testing because of expenses and time 
consumption. Venous blood was drawn from all subjects and centrifuged to separate 
serum. All serum samples were frozen at -80 degrees Celsius and were later analyzed 
simultaneously as a batch. The sensitization analyses were performed at the Clinical Lab-
oratory of the Erasmus Medical Center according to manufacturer’s protocol (Phadia AB, 
Sweden). Levels of total IgE, and specific IgE directed to inhalant allergens (cat and dog 
dander, birch pollen, grass pollen, house dust mite and herb pollen) were determined. 
Levels of serum IgE higher than 100 kU/L were considered increased15. Patients were 
sensitized to aeroallergens if the serum value of IgE directed against aforementioned 
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allergens was more than 0.35 kU/L16. The results of total serum IgE analyses were not 
available for three PSO and 1 PSA patients because of loss of samples.
Arthritis severity
PSA patients were also given the Health Assessment Questionnaire 17 (HAQ), which 
produces a Disability Index (HAQ-DI) specific for arthritis patients as well as a visual ana-
logue scale (VAS) for pain and patient global VAS. Clinical arthritis activity was assessed 
with Disease Activity Score for arthritis 18 (DAS28).
Statistics
For sample size calculations, we assumed a prevalence of 20% of atopic disorders in 
our control group10 and expected half of this proportion in PSA and PSO patients. For a 
power of 80% and an alpha level of 0.05, a sample size of 135 cases and 135 controls was 
required. The demographic characteristics and frequency of the atopic features were 
statistically compared between three patient cohorts: PSO patients, PSA patients and a 
control group. The Chi-squared test was used to test for statistical differences in propor-
tions and the Mann-Whitney U test was used to analyse the differences in nonparametric 
continuous variables (i.e. DAS28 and HAQ scores). In univariate logistic regression we 
have analyzed the effect of sex, age, methotrexate use, biological use and smoking on 
clinical and serological parameters of atopy. Variables with an effect with p<0.20 were 
included in the multivariate analyses. During preliminary analyses it was clear that the 
prevalence of atopic manifestations was not decreased in PSO patients. Therefore only 
patients with PSA were included in disease severity analyses. For the analysis of the ef-
fect of atopy on the severity of arthritis we have used sensitization to common allergens 
as definition for atopy. Sensitization to common allergens is more specific for atopy than 
total serum IgE and is more prevalent than clinical manifestations of atopy19. Variables 
were included in the multivariate models and linear regression analysis if p<0.20 in 
the univariate analysis. All data were analyzed using IBM SPSS version 19.0 (Chicago, 
Illinois). This study was approved by the medical ethical committees of Erasmus MC and 
Maxima Medical Centre (reference numbers MEC- 2007-181 and NL 1394307807) and 
was conducted in accordance with the Declaration of Helsinki.
RESULTS
demographic characteristics
A total of 448 subjects were included of which 133 patients suffered from PSO, 168 with 
PSA and 147 were controls (Table 1). The mean age was comparable over the three 
groups and varied between 49 and 54 years. The proportion of males was highest in 
37
Decreased prevalence of atopic features in patients with psoriatic arthritis, but not in psoriasis vulgaris
2
the PSO group. On average, patients with PSO were younger than patients with PSA 
at onset of their disease. The PASI score was higher in PSO patients indicating more 
severe cutaneous disease compared with PSA. Patients with PSA were more likely to be 
on methotrexate (MTX) and as likely to be on a TNF-antagonist compared to the PSO 
population (Table 1).
Table 1. The distribution of patient and disease characteristics of the three patient cohorts
Group PSO
(n=133)
PSA
(n=168)
Control*
(n=147)
Mean age, years (Sd) 49 (15.5) 52 (12.0) 54 (15.6)
Males (%) 60% 53% 44%
Age at onset in years (Sd) 31 (17.4) 41 (13.8) N/A
duration of disease, years (Sd) 30 (16.8) 11 (10.1) N/A
PASI score (Sd) 7.0 (6.8) 1.5 (2.5) N/A
dAS28 score (Sd) N/A 2.6 (1.0) N/A
Current MTX users 12% 49% N/A
Current biological users 17% 14% N/A
Current smokers 59% 27% 34%
 Family history of atopy 28% 29% 27%
Abbreviations: PSO, psoriasis vulgaris; PSA, Psoriatic Arthritis, SD, Standard Deviation, PASI, Psoriasis Area 
and Severity Index (ranges from 0-72); DAS28, Disease Activity Score 28; MTX, methotrexate; N/A, not ap-
plicable
* patients referred to the department of dermatology for varicose veins.
Of the three patient groups, PSO patients reported significantly more frequently to be 
current smokers compared to PSA and control patients. A positive family history for 
atopic disorders was observed in almost 30% for each of the groups.
Hayfever
The proportion of subjects who reported having had hayfever was lower in the PSA 
group (7.7%) than in controls (13.6%) and in PSO group (12.0%), (p=0.09 and p=0.21 re-
spectively: Figure 1). Age and methotrexate use potentially confounded the association 
between hayfever and PSA or PSO (P<0.20 in univariate analysis; Table 2). After adjusting 
for these variables in a multivariate logistic regression model, patients with PSA were 
about 50% less likely to report a history of hayfever compared to control population 
and this difference almost reached statistical significance (adjusted OR=0.48 [CI 95% 
0.23-1.03]; Table 3.). There was no difference in the likelihood of self-reported hayfever 
between PSA and PSO patients. (adjusted OR=0.91 [CI 95% 0.39-2.14])
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Figure 1. Life-time prevalences of atopic disorders and sensitization in PSO, PSA and control groups
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significant results are printed in bold.
Asthma
The percentage of subjects reporting asthma was lowest in the PSA group followed 
by controls and PSO patients (3.6% vs. 9.5% vs. 9.8%; p= 0.031 and p=0.028 Figure 1). 
The difference between PSO and controls was not statistically significant. Potential 
confounder for this association was the age (Table 2) and after adjusting for it in a mul-
tivariate model, patients with PSA were approximately 70% less likely to have a history 
of asthma compared to controls. (adjusted OR=0.34 [CI 95% 0.13-0.92]; Table 3). The 
adjusted odds ratio for the comparison between PSA and PSO was 0.38 [CI 95% 0.14-
1.04] suggesting a protective effect that was not statistically significant.
Of the 6 asthmatic PSA patients only one declared to have used inhalators in the past 
12 months. In the control group 8 of 14 individuals with asthma reported having used 
inhalators. In the PSO group there were 2 inhalator users in 13 asthmatics.
Sensitization to common aeroallergens and total serum IgE
The proportions of PSO and control patients sensitized to common aeroallergens were 
similar (35.4 % vs. 34.0%), but significantly higher than the 19.7% detected in the group 
of PSA patients (p=0.003 and p=0.004, respectively). The difference between PSO and 
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controls was not statistically significant. Methotrexate use, sex and age were associated 
with sensitization to common allergens in univariate logistic regression analysis (p<0.20; 
Table 2). After adjusting for these variables the likelihood of sensitization was about 
less than half in PSA patients compared to controls (adjusted OR=0.43 [95%CI 0.23-0.83] 
Table 3). Similar results were found for PSA vs. PSO (adjusted OR=0.53 [95%CI 0.29-0.87]). 
Comparison of PSO versus control yielded a statistically non-significant difference (ad-
justed OR=1.10 [95%CI 0.60-2.02] )
The proportions of subjects with total serum IgE levels > 100kU/L were 21.8%, 31.5% and 
12.6% for controls, PSO and PSA groups respectively. The difference in the prevalence of 
increased IgE between PSA and controls was significant (p=0.028) which was also the 
case for comparison between PSA and PSO (p<0.001). Variables potentially confound-
ing the associations with increased serum total IgE were sex, age, methotrexate use 
and smoking (Table 2). The adjusted OR for having increased total serum IgE in PSA 
vs. controls was 0.52 (95%CI 0.22-1.21; Table 3). Also, compared to PSO, PSA patients 
were significantly less likely to show elevated serum IgE levels (adjusted OR=0.35 [95%CI 
0.17-0.72]).
Table 3. Uni-and multivariate binary logistic regression analyses comparing clinical and serological mani-
festations of atopy in PSO, PSA and control groups
Atopic features PSA vs PSO PSA vs controls PSO vs controls
Crude OR
(95%CI)
Adjusted 
OR*
(95%CI)
Crude OR
(95%CI)
Adjusted 
OR*
(95%CI)
Crude OR 
(95%CI)
Adjusted 
OR* (95%CI)
Hayfever 0.61
(0.28-1.33)
0.91
(0.39-2.14)
0.53
(0.26-1.11)
0.48
(0.23-1.03)
0.87
(0.43-1.76)
0.80
(0.38-1.67)
Asthma 0.34
(0.13-0.93)
0.38
(0.14-1.04)
0.35
(0.13-0.94)
0.34
(0.13-0.92)
1.03
(0.47-2.28)
0.96
(0.43-2.15)
Sensitization to common 
aeroallergens
0.45
(0.27-0.76)
0.53
(0.29-0.96)
0.48
(0.29-0.80)
0.43
(0.23-0.83)
1.06
(0.65-1.74)
0.84
(0.49-1.45)
Total IgE
 >100ku/L
0.31
(0.17-0.56)
0.35
(0.17-0.72)
0.50
(0.27-0.91)
0.52
(0.22-1.21)
1.60
(0.93-2.72)
1.52
(0.79-2.93)
Abbreviations: PSO, psoriasis vulgaris; PSA, psoriatic arthritis; OR, odds ratio; 95%CI, 95% confidence inter-
vals;
*multivariate logistic regression model was adjusted for age, sex, methotrexate use and current smoking 
where appropriate according to univariate logistic regression analysis from table 2. Statistically significant 
results are printed in bold.
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Effect on clinical activity and course severity
To assess the impact of sensitization to common aeroallergens on clinical activity of 
arthritis in PSA the median scores of clinical PSA severity measures in sensitized and 
non-sensitized PSA patients were compared. The median DAS28 score in sensitized 
patients with PSA was nonsignificantly lower than in non-sensitized patients (2.12 (IQR 
1.78-3.11) vs. 2.60 (IQR 1.98-3.35; p=0.190).
The median HAQ VAS score for pain in sensitized PSA patients was significantly lower 
than in non-sensitized patients (0.33 [IQR 0.21-1.02] vs 1.23 [IQR 0.56-1.86 ], p<0.001). 
Similar results were obtained for HAQ patient global VAS (19.0 [IQR 5.0-35.0] vs. 45.0 [IQR 
19.0-64.0] p<0.001).
The median HAQ-DI score was significantly lower in sensitized patients with PSA 
(0.25 [IQR 0-0.75]) compared to the score in those non sensitized (0.75 [IQR 0.25-1.25], 
p=0.016). Further evaluation of these differences in a multivariate linear regression anal-
ysis revealed that the DAS28 score and HAQ-DI score were not significantly influenced 
by sensitization to common aeroallergens (Table 4). HAQ-VAS for pain and HAQ-VAS in 
PSA patients for patient global score were significantly influenced by sensitization to 
common aeroallergens (beta-coefficient -0.54 [95% CI -0.84 - -0.25] and -18.4 [95% CI 
-28.5 - -8.25] respectively.)
dISCUSSION
This study has consistently demonstrated a reduced prevalence of atopic features such 
as asthma (and to a lesser extent hayfever) and sensitization to common aeroallergens 
and increased total serum IgE in patients with PSA compared to PSO patients and 
controls. The antagonism between atopic disorders and autoinflammatory conditions 
has been found previously in type 1 diabetes mellitus20-24 and in rheumatoid arthritis9-11. 
Our data suggest that immunological mechanisms in PSA may be more similar to those 
of rheumatoid arthritis than those of psoriasis vulgaris. The research on this subject in 
patients with psoriasis whether cutaneous or arthropathic has been limited to studies 
describing concurrent existence of atopic dermatitis or allergic contact dermatitis and 
cutaneous psoriasis6, 25-27. These studies have not shown antagonism on observational 
level between psoriasis and atopic dermatitis. So far, no studies have focused on pa-
tients with PSA in this matter. The two VAS HAQ scores assessing disease severity were 
significantly lower in sensitized PSA patients and this effect was greater than that of 
confounding variables included in the forward selection mode. The HAQ-DI score was 
also significantly lower in sensitized patients but this effect was diluted in linear multiple 
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regression analysis. Disease activity score (DAS28) which is an arthritis symptom score 
did not differ between the atopic and non-atopic PSA patients. However, this study may 
have been underpowered to detect differences in disease severity
Immunological explanation
A mechanistic explanation for the found antagonism can not be deduced from our data. 
It is not clear on which level (e.g. genetic, cellular, proteomic or confounding) the cross 
regulation between atopy and psoriatic arthritis takes place. We can exclude simple 
genetics as a cause because the prevalences of family history of atopy in patients with 
psoriatic arthritis and controls were similar. Antagonism on cellular level, assuming 
an immune system skewed towards Th-2 responses in atopics, could provide a basic 
explanation. Previous studies have favoured this hypothesis. Nevertheless, unknown 
confounders can not be excluded. The difference in clinical and serological atopy be-
tween PSO and PSA is a striking finding which suggests a principal, rather than a gradual 
immunological difference between the two diseases.
Stengths and limitations
This is the largest observational study investigating the association between atopic fea-
tures and PSO and the first to study frequency of atopy in PSA patients. The PSO and PSA 
patients have all been diagnosed by dermatologists and reumatologists, respectively, to 
minimize misclassification bias. Psoriasis is a clinical diagnosis easily made after physical 
examination and CASPAR criteria have a specificity and sensitivity of over 99% for PSA28. 
The Dutch areas where both recruiting hospitals are situated do not differ with respect 
to demographic characteristics and degree of urbanisation (Rotterdam vs Eindhoven). 
The equal percentages of family history of atopy in all groups suggest similarities in 
population composition for both hospitals. Therefore, the effect of the use of different 
hospitals departments for PSO and controls vs PSA on the study findings appears to be 
limited.
The selection of an appropriate control group is challenging and we choose patients 
with varicositas as controls because it is a common condition and not known to be 
associated with inflammatory diseases. There is no commonly accepted definition of 
the diagnosis of ‘atopy’.1 Since atopy is a clinical predisposition towards development 
of atopic dermatitis, atopic asthma and hayfever, we included self-report presence of 
hayfever and asthma based on validated questoinnaires, but excluded atopic dermatitis 
because it is more difficult to distinguish from other forms of dermatitis including pso-
riasis. In addition to clinical diagnosis, serum IgE directed to common inhalant allergens 
was added.29 A limitation of all observational studies is establishing causality. However, it 
can be assumed that atopy preceded PSO and PSA because atopic disorders, in contrast 
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to PSO and PSA, occur during childhood.30 It is therefore plausible that atopic disorders 
protect against the development of psoriatic arthritis and not vice versa, but, neverthe-
less, other longitudinal observational and fundamental studies need to confirm this 
hypothesis.
In this study, self-reported (history of ) atopic dermatitis was excluded because of the 
clinical similarities to psoriasis, but it would be interesting to assess the life time preva-
lence of atopic dermatitis in psoriatics because skin is the target organ in both diseases
In conclusion, this is the first study reporting a reduced prevalence of atopic features in 
PSA and not PSO. Longitudinal cohort studies are needed to assess the causality of this 
relationship and fundamental research is needed to explore the underlying immuno-
logical mechanisms.
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To the Editor:
With great interest we read the article of Czarnowicki et al., in which local and systemic 
B-cell abnormalities in patients with atopic dermatitis (AD) were presented.1 Specifically, 
relative expansions of transitional, CD27+IgD+ memory and IgE-expressing B cells were 
found. We recently proposed a reproducible approach for identifying IgE-expressing 
B cells, and showed that the CD27-IgE+ memory B-cell subset was expanded with in-
creased levels of somatic hypermutations in patients with AD, while CD27+IgE+ memory 
B-cell and plasma cell frequencies were normal.2 In line with a multitude of other chronic 
immune diseases, Czarnowicki et al. observed more general B-cell abnormalities in pa-
tients with AD.1
Despite the extensive analysis, no attention was paid to the non-Gaussian distribution 
of cell frequencies,2-4 and no absolute numbers were reported. Such analyses as well 
as reproducibility in independent cohorts are necessary for proper understanding of 
disease pathology and for patient stratification to improve therapy success.
Therefore, we here analyzed the blood B-cell compartment of our previously published 
cohorts of patients with AD and patients with psoriasis.2 Within total CD19+ B cells, the 
naive, memory and plasma blast cell subsets were defined by multi-color flow cytometry 
(Figure 1).2, 5 In addition, IgM-only and Ig-class switched memory B cells were defined 
within the IgD- events. This allowed for reliably detection of IgE expressing B-cells 
without contamination of IgE-binding B-cells via the low FcεRII (CD23). No differences 
were found between healthy controls and psoriasis patients. AD patients did show 
significantly lower frequencies of CD27+IgD+ and CD27+IgD-IgM+ ‘IgM-only’ memory B 
cells, and an increase in CD27-IgE+ memory B cells (Figure 1C).2
Upon calculation to absolute cell numbers per microliter of blood, only the decrease of 
IgM-only memory B cells remained significant for AD patients (Figure 1D); no difference 
was seen for CD27+IgD+ B cells and the CD27-IgE+ population was not significantly 
increased (p=0.08).
Thus, in contrast to Czarnowicki et al. we did not find expansions of transitional B cells, 
CD27+IgD+ memory B cells and total or IgE+ plasma blasts in AD patients. Our cohort 
size was slightly smaller than that of Czarnowicki et al. (23 vs 34 subjects), but with a 
similarly large age range (16-79yr vs 18-74yr) and an almost equal Female/Male ratio.1, 2 
While 15/23 patients had elevated serum IgE levels, these did not range as high as in the 
Czarnowicki cohort, which might account in part for the difference between our results.
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Figure 1. Absolute numbers and relative distributions of B-cell subsets in healthy adults, patients with 
atopic dermatitis and patients with psoriasis. A. Defi nition of the major naive and memory B-cell subsets 
and plasma cells with fl ow cytometric immunophenotyping. B. Further subsetting of IgD- memory B cells 
based on diff erential expression of CD27 and the remaining 4 Ig isotypes.2, 5 C. Relative distributions of B-
cell subsets. D. Absolute numbers of total B cells and B-cell subsets. *, p<0.05; **, p<0.01; Mann-Whitney U 
test.
Another explanation could lie in the fact that we here depicted the medians and calcu-
lated statistics with the non-parametric Mann-Whitney U test, rather than mean values 
and Student’s t-test. We advocate a standardized analysis procedure to take into account 
non-Gaussian distributions, as well as calculation of absolute cell numbers to prevent 
misinterpretation of changes in co-dependent variables.6, 7 Furthermore, interpretation 
of B-cell immunophenotyping can be improved by consensus nomenclature of the B-
cell compartment.5, 8
In conclusion, the diff erent observations from the Czarnowicki cohort and ours warrant 
further detailed analysis of B-cell phenotypes in AD patients, and especially whether 
these correlate with specifi c clinical fi ndings. These detailed studies would be necessary 
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to establish whether AD patients have general abnormalities in their B-cell compart-
ment or if these are mostly limited to the expansion of IgE-expressing B cells, as this 
could have major implications for future therapeutic approaches.
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ABSTRACT
Protection against ultraviolet radiation-induced DNA-damage in the skin is not only pro-
vided by the pigmentary system. The epidermal barrier consisting of stratum corneum 
keratinocytes, filaggrin and other proteins is an additional component of the UV-shield. 
Disruption of the epidermal barrier through frequent body cleansing with soaps and 
cosmetics may increase the risk of non-melanoma skin cancer.
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INTROdUCTION
Since the 1950s it is known that excessive exposure to ultraviolet radiation (UVR) is 
associated with an increased risk of nonmelanoma skin cancer [1]. Non-melanoma 
skin cancer is the term which covers basal cell carcinoma (BCC) and squamous cell 
carcinoma (SCC). UVB and UVA are both oncogenic and immunosuppressant, but UVB 
mostly acts through direct mutagenic oncogenesis while UVA’s effects mainly impair 
the immunosurveillance. The current leading theory, fueled by overwhelming epide-
miologic evidence is that epidermal protection against skin cancers is solely provided 
by the pigmentary system. This barrier of melanin produced by melanocytes in the basal 
layer of the skin is transferred to the keratinocytes via melanosomes. The mismatch 
between skin phototype (degree of pigmentation) and UVR exposure has become a 
truism to explain the rise in incidence of non-melanoma skin cancer. This mismatch is 
the single most important risk factor for non-melanoma skin cancer which has left little 
room for research on alternative risk factors. The currently failing prevention programs 
necessitate the analysis of preventable causes [2]. Here, we propose epidermal barrier 
dysfunction through personal hygiene habits as a new risk factor for the development 
of non-melanoma skin cancers.
Why pigmentation only does not suffice
Melanin is thought to protect the skin from the DNA-damaging effects of UV-light. The 
lower prevalence of non-melanoma skin cancer in dark skinned individuals underscores 
this. Nevertheless, the existence of DNA-repair mechanisms in the skin indicate that 
pigment only may not suffice to protect us. The rare cases of African patients with 
xeroderma pigmentosum illustrate this in vivo. These patients develop squamous cell 
carcinomas in the typical photodistributed locations very early in their lives [3].While 
a darker skin type in healthy Africans does offer protection against nonmelanoma 
skin cancer, facultative pigmentation as seen in people of European ancestry offers no 
protection against development of UV-induced pyrimidine dimers [4]. Pheomelanin 
even induces apoptosis of keratinocytes as it acts as a photosensitizer after exposure 
to UVB [5]. Although the pigmentary system protects us from acute sunburn, the de-
velopment of non-melanoma skin cancer does not threaten the survival of individuals 
before reproductive age. In the anogenital area, the squamous cell cancer arises without 
significant, previous UVB-exposure. This is explained by the oncogenic effects of human 
papillomavirus and indicates the existence of alternative and complementary routes of 
pathogenesis from which melanin offers no protection.
Chapter 3.1
58
Stratum corneum as UvR-barrier
There is more in the epidermis than pigment only to block the UVR. The most outer layer 
of the skin, stratum corneum, is the first component of the skin to absorb the photons. It 
is known that low doses of UVR from the ambient spectrum may not even penetrate stra-
tum corneum [6]. Thickening of the stratum corneum is the most important adaptation 
to acute UVR-exposure in humans [7]. In a study with vitiligo patients, the skin stripped 
of stratum corneum was significantly more sensitive to UVB in terms of mean erythema 
dose than non-stripped skin [8]. Besides the dead keratinocytes and their contents the 
photons from UVR also encounter a barrier of many proteins, amino acids, ceramides 
and lipids in stratum corneum. Stratum corneum, together with all these components 
is also referred to as the epidermal barrier. This barrier is held in place by a scaffold of 
filaggrin. Filaggrin is a protein which contributes to compaction of stratum corneum 
and cohesion between its constituents [9]. Impairments in the functioning of filaggrin, 
its precursors or derivatives have been linked to inflammatory skin disorders like atopic 
dermatitis but may also lead to a disrupted epidermal UVR-barrier. A study with a human 
skin model showed increased UVB-induced apoptosis after
knockdown of filaggrin expression [10]. Conversely, in response to UVB-exposure filag-
grin expression is upregulated together with other components of the epidermal barrier 
[11]. Derivatives of the filaggrin metabolism also may provide protection against UVB 
induced effects. Filaggrin cleavage by caspase-14 is required for its proper functioning. 
A major derivative of the cleavage process of filaggrin by caspase-14 is urocanic acid. 
Urocanic acid provides protection against dehydration and low-level protection against 
UVB-induced DNA-damage [12]. The skin of caspase-14-deficient mice is highly sensitive 
to the formation of pyrimidine dimers after exposure to UVB compared to wild type 
mice [13]. These data strongly suggest that the stratum corneum provides an additional 
component for the total UVR barrier.
EPIdERMAL BARRIER dySFUNCTION ANd SKIN CANCER
Previously mentioned studies have demonstrated increased sensitivity to UVR in dys-
functional stratum corneum but there is also circumstantial evidence that defects in the 
stratum corneum may actually lead to non-melanoma skin cancer. Patients with skin 
disorders primarily related to epidermal barrier dysfunction have been of particular 
interest. In a Danish cohort of 31,330 patients with atopic dermatitis, a common disorder 
of the epidermal barrier the standardized incidence ratios for BCC and SCC were 1.41 
[95% CI 1.07-1.83] and 2.48 [95% CI 1.00-5.11] respectively [14]. Patients with epidermal 
barrier dysfunction are also frequently sensitized to various allergens because of the 
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more permeable epidermis. They develop antibodies of the IgE-type. Patients who have 
multiple squamous cell carcinomas have these antibodies more often (odds ratio 3.82 
[95% CI 1.05-13.88]) [15]. This suggests that patients with an impaired epidermal barrier, 
which is indicated by the presence of sensitization to common allergens, are at higher 
risk of developing non-melanoma skin cancer. Same results can be found in non-vulgaris 
ichthyosis and Netherton’s syndrome. These rare disorders are extreme examples of 
epidermal barrier dysfunction. Patients with these disorders show an increased suscep-
tibility to squamous cell carcinoma [16]. In Netherton’s syndrome a mutation in SPINK5 
leads to impaired function of a serine protease inhibitor. The proteases which it inhibits 
are involved in desquamation and remodeling of the stratum corneum and processing 
of filaggrin. These patients often have an atopic dermatitis-like phenotype and exhibit 
high serum-levels of IgE.
How the hygiene may contribute
The epidermis is continuously exposed to physical and chemical assaults. Of all physical 
agents application of detergent is the most damaging to the anatomy and function of 
stratum corneum [17]. Through personal hygiene habits our skin is frequently exposed to 
warm water during showering and to detergents from soaps and cosmetics. This hygiene 
behaviour and lifestyle is a relatively recent development in human evolution and our 
skin may not be adapted to it. Dermatologists typically discourage vigorous use of soap 
and frequent showering for patients with atopic dermatitis. From anecdotal evidence 
we know that this may worsen the disease. However, no high-level evidence exists to 
back this practice up. Even less is known about the influence of hygiene and cosmetic 
products on the skin in healthy individuals. The use of showering gels impairs the func-
tion and damages the stratum corneum [18]. This is probably mostly attributable to the 
effects of sodium lauryl sulphate which is ubiquitous in commercially available products 
[19]. When in contact with skin it initiates denaturation of the epidermal proteins which 
subsequently leads to an impaired epidermal barrier function [20]. Filaggrin is water-
soluble. Therefore, even exposure to only water during washing may rinse of significant 
amounts of the epidermal scaffolding which takes some time to replace. We postulate 
that frequent exposure to showering and detergents in soaps and cosmetics, as habitu-
ally used in modern times, lowers epidermal UVR-blocking capacities and increases the 
risk of non-melanoma skin cancer.
TESTING THE HyPOTHESIS
Future studies may encounter some problems. It will be difficult for the fundamental 
scientist to define hygienic behaviour in animal models and dysfunctional skin barrier. 
Chapter 3.1
60
This makes the results hard to interpret and to extrapolate to humans and clinically rel-
evant endpoints. Genetic studies may reveal polymorphisms influencing the epidermal 
barrier and the development of nonmelanoma skin cancer but the practice of hygiene 
is obviously a cultural phenomenon which cannot be taken into account within these 
studies. Functional testing with measuring of the epidermal barrier function is not fea-
sible in large groups of patients and the time until the development of skin cancer may 
blur the results. Also, the amount of damage to the skin barrier through external factors 
needs defining especially in longitudinal cohort studies. The testing of our hypothesis 
therefore necessitates research involving different areas. In vitro studies should focus 
on how stratum corneum and filaggrin protect us against UVR-induced DNA-damage 
and how this may be impaired by environmental factors. Genetic studies are needed 
to help form new hypotheses. Epidemiologic studies may show or dispute associations 
between diseases of the epidermal barrier such as atopic dermatitis and non-melanoma 
skin cancer. This is a cumbersome field because of many potential confounders such as 
use of immunosuppressant medication and treatment with UVR. The role of hygiene 
and cosmetics as well as exposure to yet unknown environmental factors should be 
explored. After the identification of relevant epidemiologic, genetic and biologic 
parameters interventional studies can be initiated. Though randomizing patients into 
“hygienic” and “less hygienic” groups may be unthinkable for longer periods of time, 
it is feasible to have two groups of individuals practicing different hygiene behaviours 
during holidays when disproportionate exposure to UVR takes place. Finally, the gained 
knowledge can be implemented through prevention studies.
REFERENCES
 1. Blum HF. Sunlight as a casual factor in cancer of the skin of man. J Natl Cancer Inst 1948;9:247-58.
 2. Madan V, Lear JT, Szeimies RM. Non-melanoma skin cancer. Lancet 2010;375:673-85.
 3. Chidzonga MM, Mahomva L, Makunike-Mutasa R, Masanganise R. Xeroderma pigmentosum: a 
retrospective case series in Zimbabwe. J Oral Maxillofac Surg 2009;67:22-31.
 4. Niggli HJ. Comparative studies on the correlation between pyrimidine dimer formation and 
tyrosinase activity in cloudman S91 melanoma cells after ultraviolet-irradiation. Photochem 
Photobiol 1990;52:519-24.
 5. Takeuchi S, Zhang W, Wakamatsu K, et al. Melanin acts as a potent UVB photosensitizer to cause 
an atypical mode of cell death in murine skin. Proc Natl Acad Sci USA 2004;101:15076-81.
 6. Phan TA, Halliday GM, Barnetson RS, Damian DL. Melanin differentially protects from the initiation 
and progression of threshold UV-induced erythema depending on UV waveband. Photodermatol 
Photoimmunol Photomed 2006;22:174-80.
 7. Pearse AD, Gaskell SA, Marks R. Epidermal changes in human skin following irradiation with either 
UVB or UVA. J Invest Dermatol 1987;88:83-7.
61
Non-melanoma skin cancer: the hygiene hypothesis
3
 8. El-Khateeb EA, Ragab NF, Mohamed SA. Epidermal photoprotection: comparative study of nar-
rowband ultraviolet B minimal erythema doses with and without stratum corneum stripping in 
normal and vitiligo skin. Clin Exp Dermatol 2011;36:393-8.
 9. Sandilands A, Sutherland C, Irvine AD, McLean WH. Filaggrin in the frontline: role in skin barrier 
function and disease. J Cell Sci 2009;122:1285-94.
 10. Mildner M, Jin J, Eckhart L, et al. Knockdown of filaggrin impairs diffusion barrier function and 
increases UV sensitivity in a human skin model. J Invest Dermatol 2010;130:2286-94.
 11. Hong SP, Kim MJ, Jung MY, et al. Biopositive effects of low-dose UVB on epidermis: coordinate 
upregulation of antimicrobial peptides and permeability barrier reinforcement. J Invest Dermatol 
2008;128:2880-7.
 12. Barresi C, Stremnitzer C, Mlitz V, et al. Increased sensitivity of histidinemic mice to UVB radia-
tion suggests a crucial role of endogenous urocanic acid in photoprotection. J Invest Dermatol 
2011;131:188–94.
 13. Denecker G, Hoste E, Gilbert B, et al. Caspase-14 protects against epidermal UVB photodamage 
and water loss. Nat Cell Biol 2007;9:666-74.
 14. Jensen AO, Svaerke C, Kormendine Farkas D, Olesen AB, Kragballe K, Sorensen HT. Atopic derma-
titis and risk of skin cancer: a Danish nationwide cohort study (1977-2006). Am J Clin Dermatol 
2012;13:29-36.
 15. Wiemels JL, Wiencke JK, Li Z, Ramos C, Nelson HH, Karagas MR. Risk of squamous cell carcinoma 
of the skin in relation to IgE: a nested case-control study. Cancer Epidemiol Biomarkers Prev 
2011;20:2377-83.
 16. Natsuga K, Akiyama M, Shimizu H. Malignant skin tumours in patients with inherited ichthyosis. 
Br J Dermatol 2011;165:263-8.
 17. Tagami H, Kobayashi H, Zhen XS, Kikuchi K. Environmental effects on the functions of the stratum 
corneum. J Invest Dermatol Symp Proc 2001;6:87-94.
 18. Gloor M, Wasik B, Gehring W, Grieshaber R, Kleesz P, Fluhr JW. Cleansing, dehydrating, barrier-
damaging and irritating hyperaemising effect of four detergent brands: comparative studies 
using standardised washing models. Skin Res Technol 2004;10:1-9.
 19. Fluhr JW, Kelterer D, Fuchs S, et al. Additive impairment of the barrier function and irritation by 
biogenic amines and sodium lauryl sulphate: a controlled in vivo tandem irritation study. Skin 
Pharmacol Physiol 2005;18:88-97.
 20. Wolf R, Parish LC. Effect of soaps and detergents on epidermal barrier function. Clin Dermatol 
2012;30:297-300.

C
ha
pt
er
 
3.2
Atopic dermatitis is not associated with actinic keratosis: cross-
sectional results from the Rotterdam study
Enes Hajdarbegovic, Hannah Blom, Joris Verkouteren, Albert Hofman, Loes Hollestein, 
Tamar Nijsten
Br J Dermatol. 2016 Jan 29. Epub
Chapter 3.2
64
ABSTRACT
Background
Epidermal barrier impairment and altered immune system in atopic dermatitis (AD) may 
predispose to ultraviolet induced DNA damage.
Objective
To study the association between atopic dermatitis and actinic keratosis (AK) in a 
population-based cross-sectional study.
Methods
AD was defined by modified criteria of the U.K. working party’s diagnostic criteria. The 
AKs were diagnosed by physicians during a full-body skin examination and keratinocyte 
cancers were identified via linking to the national pathology database. The results were 
analysed in adjusted multivariable and multinomial models.
Results
Lower proportion of subjects with AD had AKs than without AD (16% vs 24%, p=0.002; 
unadjusted OR 0.60; 95% CI, 0.42-0.83, adjusted 0.74; 95% CI, 0.51-1.05, fully adjusted 
0.69; 95 CI, (0.47-1.07)). In a multinomial model AD patients were less likely to have 10 
or more AKs (adjusted OR 0.28; 95% CI, 0.09-0.90). No effect of AD on BCC and SCC was 
found (adjusted OR 0.71; 95% CI, 0.41-1.24 and adjusted OR 1.54; 95% CI, 0.66-3.62).
Conclusion
AD in community dwelling patients is not associated with AK.
What is already known
* Patients with severe AD treated with UV and immunosuppressants are at an increased 
risk of keratinocyte malignancies.
What does this study add?
* Community dwelling, average AD patients do not have more AKs or KCs.
* There is no support for extra AK and KC screening in patients with mild to moderate 
AD.
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Abbreviations
AD; Atopic dermatitis
AK; Actinic keratosis
AR; Allergic rhinitis
BCC; Basal cell carcinoma
CI; Confidence interval
IRR; Incidence rate ratio
KC; Keratinocyte cancer
OR; Odds ratio
RS; Rotterdam study
SCC; Squamous cell carcinoma
UVB; Ultraviolet-B
UVR; Ultraviolet radiation
95% CI; 95% confidence interval
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INTROdUCTION
Atopic dermatitis (AD) is one of the most prevalent inflammatory skin conditions affect-
ing up to 30% of infants and up to 10% of adults and its incidence has tripled in the past 
three decades.1 Atopic dermatitis results from an impaired epidermal barrier, mostly due 
to mutations in the filaggrin gene, combined with an overactive, Th2-polarized immune 
system. 2 It has been shown that the defective barrier may predispose AD patients to 
more ultraviolet radiation (UVR) induced DNA damage and subsequently increase the 
risk of keratinocyte cancers (KCs). There is, however, also ample evidence that increased 
epithelial turn-over and enhanced immunosurveillance actually protect against carcino-
genesis in the atopic skin.6,7
KCs are common and their incidence is still increasing, which is most likely due to chang-
es in UV exposure patterns. 5 Basal cell carcinoma (BCC) is the most common cancer in 
people of European ancestry. Squamous cell carcinoma (SCC) occurs at a comparable 
rate with melanoma, especially in elderly individuals and those chronically exposed 
to the sun. 8, 9 Actinic keratosis (AK) is a keratinocyte premalignancy and is also highly 
prevalent (25% of Dutch inhabitants older than 50 years of age) and is associated with 
high levels of cumulative UV exposure. 10,11
In several mice studies, altered filaggrin expression and metabolism have been dem-
onstrated to lead to an increased susceptibility to UVB-induced DNA damage.4,5,12-14 In 
humans the results are inconsistent and the studies lack clear definition of exposure. 
Filaggrin loss-of-function mutations were not associated with incident skin cancer in a 
Danish cohort of 13376 genotyped individuals15. Three retrospective registry based co-
hort studies observed a 1.5 to 2.5 folds increased risk of developing KC in patients with 
AD, but these studies suffered from substantial residual confounding.16-18 In contrast, 
four small retrospective studies suggested no association between AD and KC19-22 and 
one mail survey including 254 AD patients suggested that AD had a protective effect on 
the development of KC.23 None of these observational studies reported the association 
between AD and AK. The objective of this study was to investigate whether subjects 
with AD have more AKs than non-AD individuals in a population-based Dutch cohort 
(i.e. the Rotterdam Study). 24
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METHOdS
Study design and study population
The Rotterdam study (RS) is an ongoing prospective, Dutch population-based cohort 
study that follows the inhabitants of the Ommoord district of Rotterdam, the Nether-
lands since 1990. 24
Currently there are 14926 participants in the RS. The RS reflects the population of the 
Netherlands in terms of co-morbidities and health consumption. Dermatologic screen-
ing was introduced in August 2010. Since then, FBSE (full body skin examination), with 
the exception of the feet and the skin covered by socks and underwear, respectively 
are being conducted by four dermatologists trained physicians focussing on the most 
common skin diseases such as skin (pre-)malignancies, atopic dermatitis, hand eczema, 
psoriasis, and varicose veins. These were a predefined set of findings and diagnoses. All 
participants of the RS are to undergo FBSE consecutively without a particular order. Par-
ticipants who had undergone FBSE were included in the present study. All were above 
50 years of age and 95% were Caucasian.
The RS is approved by the Medical Ethics Committee of the Erasmus University Medical 
Centre and The Netherlands Ministry of Health. All patients participating in the study 
gave written informed consent. This study is a cross-sectional study drawn from the 
Rotterdam study.
Exposure: Atopic dermatitis
The participants were interviewed at home and FBSE was performed by trained physi-
cians in a medical research facility in the centre of the district. No validated diagnostic 
criteria exist for adults with AD. However, in our practice, adults are diagnosed with AD 
on a daily basis. Therefore the commonly used UK working party’s criteria, designed for 
a paediatric population needed adjusting before they could be applied to our elderly 
population. 25 These guidelines comprise one major criterion plus three or more minor 
criteria. ‘An itchy skin condition’ is the must have criterion and the minor criteria are: 
‘history of involvement of the skin creases’, ‘a personal history of asthma or hay fever’, ‘a 
history of generally dry skin in the last year’, ‘visible flexural eczema’ and ‘onset under 2 
years of age.
Because of the possible confusion of sun damaged skin and hyperkeratosis of AK with 
xerosis and because of the high prevalence of dry skin in the elderly (56% in patients 
in the RS), the item of ‘history of generally dry skin’ was excluded from our AD defini-
tion. 26 The personal history of other atopic diseases was extended with ‘house dust 
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mite allergy’, because it is strongly related to atopic diseases.27 Furthermore sites of 
visible eczema were adapted. In adults, atopic dermatitis also occurs on the hands 
and the trunk.28 We therefore included these localisations. Finally the onset of age was 
prolonged to twelve years of age, because most patients develop AD before this age.25 
Atopic dermatitis could contribute to the development of AK’s through either the defect 
in the epidermal barrier or the chronic inflammation in the skin. In order to be able 
to differentiate between these two hypotheses we performed analyses on AD criteria 
separately. In the case of the barrier-model one would expect all patients with AD to 
have an increased risk while in the case of chronic inflammation-model patients with 
current, i.e. long standing AD would be at more risk.
Outcome: Actinic keratosis
As previously reported in a prevalence study within RS, AKs were diagnosed by trained 
physicians and were defined as a rough (keratotic) lesion with adherent scaling and 
erythema, not fitting other diagnoses.11 The cumulative number of observed AKs was 
divided into 4 categories: 0, 1-3, 4-9 or ≥10 AKs. Limiting the reporting of AK to catego-
ries instead of a continuous variable prevents inter-rater variability to some degree and 
makes for a clinically more relevant outcome corresponding with: no AK, mild, moderate 
and severe AKs.
Outcome: keratinocyte cancer
As described previously, the BCCs and SCCs were histologically confirmed by linking the 
RS participants to PALGA, a network of histo- and cytopathology which administrates 
the information of all biopsies and excisions from 1991 onward on a national level.11 If at 
the time of the skin examination, suspicious lesions were observed they were biopsied, 
treated and included if pathologically confirmed as BCC or SCC.
Covariates
Previously identified risk factors for AK such as gender, age and pigmentation status 
were integrated in our analyses.11 Pigmentation status was defined as a combination 
of three variables: hair colour at young age, eye colour and skin colour. The variable 
‘hair colour’ contained 4 categories (fair/blonde, dark blonde/brown, red and black), ‘eye 
colour’ 3 categories (blue, intermediate, brown) and ‘skin colour’ had 6 options (albino, 
white, white to olive, light brown, brown, dark brown to black). The sum of the variables 
was recoded into three categories of light, medium or dark pigmentation status. Male 
baldness at the time of the skin examination was also recorded as a binary variable. Other 
possible risk factors for AKs were available from interview data: living in a sunny country 
for >1 year, the use of immunosuppressive medication , smoking, wearing sunglasses 
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and hats for protection, and the number of life time sunburns. The first three questions 
had binary responses and the last two were categorized as never/almost never, often/
not always and always, and the absolute number of sunburns. These variables are not 
known for an association with AD, but because of their importance as a traditional risk 
factor for AKs, they were taken into account and they were used in the fully adjusted 
model.27 Finally, we only included possible confounders with effects greater than 10% 
on the association between atopic dermatitis and AK in the main adjusted model (i.e. 
bivariate approach for selection of confounders).29
Statistical analysis
The null hypothesis was that AD is not associated with AK in a population based sample. 
The sample size for this study was calculated a priori and was based on a power of 80%, 
an altered risk of one third (OR of ≤0.66 or ≥1.33), based on an estimated AD prevalence 
of 10%. The calculated sample size (number of cases) for these ORs lies between 829 and 
1253. It was powered for a univariate analysis for the association between AK and AD as 
SCC and BCC are not prevalent enough to provide over 829 cases. The primary analyses 
were performed by univariable and multivariable binary logistic regression looking at 
the association between AD and AK, SCC and BCC, separately. In a multinomial logis-
tic regression model, the number of AKs was also analysed by categories namely 1-3 
AKs, 4-9 AKs and >10 AKs, to assess whether the number of AKs changed the effect in 
relation to AD. Sensitivity analysis was performed to investigate whether having active 
dermatitis or past history of it or history of atopy was driving a potential association 
and whether altering the definition of exposure would alter the OR of the association. 
Individuals with missing variables relevant for the analyses were excluded. Values of 
p<0.05 were considered significant. All data were analysed using IBM SPSS 21.0, except 
for the sample size calculation; PS Power and Sample Size Calculations Version 3.0.
RESULTS
Patient characteristics
 An FBSE and home interview were carried out in a total of 4,375 participants. The 
proportion of females in the cohort was 56% and the mean age was 67.6 years (range 
53-100) (Table 1). Of the 4,375 participants, 24% had one or more AK of which 56.9% had 
1-3 AKs, 22.8% had 4-9 and 20.4% had more than 10 AKs. The mean age of subjects with 
AKs was significantly higher than those without AKs, 73 vs 65.9 years (p<0.01).
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Table 1. Frequencies and characteristics of the study population*
Cases/AK (N=1050) Controls/No AK (N=3325) P-value
Characteristic N (%) N %
Ad criteria P = 0.002
No 1006 (95.8) 3107 (93.4)
Yes 42 (4.0) 218 (6.6)
Missing 2 (0.2) 0 (0.0)
Gender P < 0.001
Women 444  (42.3) 1988 (59.8)
Men 606 (57.7) 1337 (40.2)
Age P < 0.001
Mean age in years (SD) 73.0 65.9
<70 379  (36.1) 2373 (71.4.)
70-79,99 483 (46.0) 764 (23.0)
≥80 188 (17.9) 188 (5.7)
Pigmentation status (eye, hair and 
skin colour)
P < 0.001
Dark 55 (5.2) 450 (13.5)
Medium 667 (63.5) 2190 (65.9)
Light 260 (24.8) 528 (15.9)
Data missing 68 (6.5) 157 (4.7)
Tendency to develop sunburn P < 0.001
Low 521 (49.6) 2165 (65.2)
High 366 (34.9) 947 (28.5)
Data missing 163 (15.5) 210 (6.3)
History of living in a sunny country 
>1 year
P = 0.003
No 820 (78.1) 2783 (83.7)
Yes 73 (7.0) 367 (11.0)
Data missing 157 (15.0) 175 (5.3)
Sun-protective behaviour P < 0.001
Never/almost never 255  (24.3) 1151 (34.6)
Often/not always 298 (28.4) 937 (28.2)
Always 340 (32.4) 1062 (31.9)
Data missing 157 (15.0) 175 (5.3)
* cumulative percentages may not be 100% in all cases because of rounding
Ad and AK
Of 4375 screened participants 6.3% met the AD-criteria. A significantly lower proportion 
of people with atopic dermatitis had actinic keratosis compared to those without atopic 
dermatitis (16% vs 24%, p=0.002; unadjusted 0.60; 95% CI, 0.42-0.83) (Table 2). Of all the 
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available potential confounders (Table 2), only age and gender changed the OR between 
AD and AK by at least 10% and were, therefore, included in the main multivariate model. 
After adjusting for age and gender, the association between AD and AK was not sig-
nificant (adjusted OR 0.74; 95% CI, 0.51-1.05; Table 2). Comparable OR was found in the 
fully adjusted model 0.69; 95% CI, (0.47-1.07). In the multinomial model taking the AK 
categories into account, 1-3 AKs and 4-9 AKs showed no significant association with AD 
in both the unadjusted and age and gender adjusted and fully adjusted analyses (Table 
2). In contrast to these low-number AK categories, AD patients were approximately 78% 
less likely to have 10 or more AKs compared to those without AD (adjusted OR 0.28; 95% 
CI 0.09-0.90). However this association did not remain significant in the fully adjusted 
model. The decreasing OR followed a statistically significant trend (p<0.001) (table2).
Table 2. Binary logistic regression of the association between AD and AK, unadjusted and adjusted models.
N=4113
Method Number of AK’s
Unadjusted OR (95% 
CI)
Adjusted* OR 
(95% CI)
Fully adjusted** 
OR(95% CI)
Binary logistic 
regression AK ≥1 0.60 (0.42-0.83) 0.74 (0.51-1.05) 0.69 (0.47-1.07)
Multinomial logistic 
regression*** AK 1-3 0.75 (0.51-1.12) 0.89 (0.60-1.33) 1.12 (0.64-1.96)
AK 4-9 0.56 (0.28-1.11) 0.75 (0.37-1.50) 0.75 (0.27-2.08)
AK ≥10 0.20 (0.07-0.64) 0.28 (0.09-0.90) 0.19 (0.03-1.43)
*adjusted for gender and age
**adjusted for gender, age, pigmentation status, history of living in a sunny country, sun protective behav-
iour, male baldness, number of sunburns, smoking and use of immunosuppressive medication
*** reference category 0 AK, p<0.001 for trend in decreasing ORs across AK categories
In order to determine which of the AD criteria were driving the association (barrier de-
fect or chronic inflammation), we analysed the criteria separately. From the total group 
of 260 persons diagnosed with AD, 92 had active dermatitis, in 209 there was flexural 
involvement, 169 had a history of atopy and 119 were diagnosed with eczema before 
the age of 12. The (un)adjusted odds ratios for these criteria are shown in table 3. Two 
minor criteria, active dermatitis and atopy in history had a significant effect on the AD-AK 
association adjusted OR 0.57; 95% CI, 0.42-0.77 and 0.75; 95%CI, 0.60-0.92 respectively. 
Exclusion of hand dermatitis from the analysis did not alter the OR essentially, however 
the CI became insignificant due to loss of power OR 0.62; 95% CI 0.25-1.55 and aOR 0.70; 
95%CI (0.27-1.84).
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Table 3. Binary logistic regression models (unadjusted/adjusted) for the association between AK and sepa-
rate AD-criteria
variable Cases (N) Controls (N) Unadjusted OR (95% CI) Adjusted* OR (95% CI)
Ad criteria (all) 42 218 0.60 (0.42-0.83) 0.74 (0.51-1.05)
Hand dermatitis 
excluded
Active dermatitis
34
60
170
292
0.62 (0.25-1.55)
0.63 (0.47-0.84)
0.70 (0.27-1.84)
0.57 (0.42-0.77)
Atopy in history 142 608 0.62 (0.51-0.76) 0.75 (0.60-0.92)
Eczema diagnosed 
<12 years
49 221 0.73 (0.53-1.00) 0.91 (0.65-1.27)
Flexural itch in 
history
101 407 0.84 (0.66-1.06) 0.98 (0.76-1.26)
* adjusted for gender and age
Ad and keratinocyte cancers
Of the 4.375 people in the RS, 350 (8%) had one or more BCCs of whom 16 persons had 
AD and 336 did not have AD (p=0.100). In binary logistic regression having AD did not 
increase the likelihood of having a BCC with and without adjustment for age and gender 
(OR 0.64; 95% CI, 0.37-1.11 and adjusted OR 0.71; 95% CI, 0.41-1.24). Seventy-eight per-
sons had one or more SCCs. Six of them had AD and 72 did not meet the criteria for AD 
(p=0.500). AD did not change the likelihood of having a SCC with an unadjusted odds 
ratio 1.33 (95% CI, 0.57-3.08) and adjusted OR1.54 (95% CI, 0.66-3.62).
dISCUSSION
Our findings suggest that within a population based sample, AD patients do not have 
more AKs than the rest of the population. Moreover, this study indicates that in individu-
als with AD the odds of having more than10AKs are significantly lower. A gradient of 
decreasing ORs with the increasing number of AKs was discernible suggesting a biologi-
cal effect. We did not find significant associations between KCs (both BCC and SCC) and 
atopic dermatitis. However, this study was not powered for the subanalyses and for the 
association between AD and BCC and SCC. Nonetheless, the results of our study suggest 
that the average, community-dwelling AD-patients are not at an increased risk of AK and 
keratinocyte cancers.
In the past, two hypotheses explained the associations between AD and KC. One dic-
tates that the overactive, atopic immune system in AD brings about increased immu-
nosurveillance of neoplastic cells while the other implies that the impaired epidermal 
barrier of AD actually predisposes to more UV-induced damage and subsequent KC.3 
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When analysing the AD criteria separately it appears that the minor criterion ‘active 
dermatitis’ is the strongest driver of the negative association suggesting that patients 
with long-standing and/or active AD are more protected . Actinic keratoses are usually 
accompanied by erythema and inflammation which can be visualised by histopathology. 
This inflammatory response can lead to spontaneous remission of immunogenic AKs. 
Eczematous skin may mount this inflammatory response more easily.7 An alternative ex-
planation for the protective effect we have found may be the locally increased turn-over 
of the keratinocytes or altered signalling between keratinocytes and immune cells.6,30 A 
cohort-study of 57815 patients who had been tested for total serum IgE and Phadiatop 
revealed no effect of serological atopy on the incidence of various cancers including 
KCs. This suggests no general protective effect of systemic atopy.31 It is also possible 
that a difference in behaviour between AD patients and control could explain the differ-
ence. For example, AD-patients may be more aware of their skin and sun damage and 
may be more adherent to sun protective behaviours. There is a possibility of detection 
bias if patients with AD present to physicians more often and have their AKs treated. 
Furthermore, AD patients may be more skilled in the correct and frequent application 
of sunscreens or may avoid sun in general because of embarrassment with skin lesions.
This is the first study to examine the association between AD and AK. The strengths 
of this study are the large number of patients, the fact that the presence of AK was 
diagnosed by trained physicians and that the number of AKs was established in detail. 
Furthermore we took into account several confounders, which enhances the validity of 
the study. There are some limitations to this study. This was a cross-sectional study. The 
outcome (AK) has been determined by a single measurement without longitudinal data. 
AK and AD have very differing ages of peak prevalence. In fact, the development of AD 
may be preceded by the development of AK by decades which makes a longitudinal 
study starting at age of onset of AD during up to the age of 40 when first AKs appear 
impossible at this moment. This necessitates retrospective ascertainment of exposure 
/ AD to some degree. There are no validated AD diagnostic criteria for adults. The use 
of modified UK working party´s criteria may have led to the inclusion of other forms of 
eczema. This would lead to a dilution of effect. The group which met the AD criteria com-
prised 6.9% of the total study population. This is comparable to the prevalence of AD in 
children from the 40’s and 50’s (childhood years in our study population), as described 
in literature.32 Moreover, the exclusion of hand dermatitis in our sensitivity analyses 
did not lead to different results. Unfortunately we could not assess the overlap in skin 
areas for eczematous skin and actinic keratoses. In this study we did not know which 
patients received treatment for severe AD like immunosuppressants and UVB therapy. 
These treatments contribute to the risk of cutaneous (pre)malignancies and may have 
led to uncontrolled confounding of AD on AK and KC risk and could explain why some 
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of the studies in AD-cohorts have found an increased risk. However, our AD-patients 
are community dwelling and the percentage of severe AD treated by these modalities 
is expected to be low. Several previous studies have also found an inverse relationship 
between atopic dermatitis and KC. One case-control study showed an adjusted OR 0.78; 
95% CI, 0.61-0.98, but the authors used subjects with other cutaneous diseases as the 
control group, which might have influenced their results.23 Margolis et al. found similar 
results, but selected their controls out of a ‘dermatitis’ group. Kaae et al. examined the 
filaggrin gene mutation status and found non-significant odds ratios below 1.00. They 
concluded that filaggrin mutation carrier-status is not important for the association 
between AD and BCC.33
However the pathomechanism remains unclear. Future studies should focus on physi-
cian-made diagnosis of AD as well as on the filaggrin gene status as exposures. It is also 
necessary to examine if the sites of KCs and AKs overlap with the skin areas affected by 
atopic dermatitis.
CONCLUSION
Patients with AD were not found to have more of AKs or KCs. Moreover, individuals with 
atopic dermatitis seem to be less likely to develop multiple AKs.
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Erasmus University Rotterdam; the Dutch Organization for Health Research and Devel-
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Atopic dermatitis is not a protective factor for melanoma but 
asthma may be.
Enes Hajdarbegovic, Nasirah Atiq, Robert van der Leest, Bing Thio, Tamar Nijsten
Int J Clin Oncol. 2014 Aug;19(4):708-11.
Chapter 3.3
78
ABSTRACT
Background: There is evidence from cohort studies for an inverse association between 
atopic dermatitis and asthma and cutaneous melanoma. However, these studies have 
been too heterogeneous and did not show statistically significant results. Also, this as-
sociation has not been compared to traditional melanoma risk factors.
Objectives: To test for associations between history of atopic disorders and melanoma 
life time prevalence. To test for associations between atopic disorders and melanoma 
prognosis.
Methods: Validated questionnaires from the European Community Respiratory Health 
Survey and International Study of Asthma and Allergies in Children protocol on life time 
prevalence of atopic disorders were sent to 280 patients with histopathologically con-
firmed melanoma. The control group consisted of their spouses. Also the skin phototype 
was assessed using a validated questionnaire.
Results: One hundred and eighty four melanoma patients and 169 controls responded 
to the questionnaire. The life time prevalence of atopic dermatitis and hayfever was 
not different in melanoma patients( 8.7% vs. 8.2 p=0.890 and 15.2% vs. 18.3% p=0.432 
respectively). Asthma was non-significantly lower in melanoma patients (3.8% vs. 8.2% 
p=0.075). Atopic melanoma patients did not differ from non-atopic patients in terms of 
Breslow thickness, metastases and second melanomas.
Conclusion: Atopic dermatitis is not a protective factor in cutaneous melanoma but a 
history of asthma may be.
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BACKGROUNd
Cutaneous melanoma is one of the most aggressive malignant tumours and is virtually 
incurable after metastasis. It is known for its rapid growth and the ability to metastasize 
early via the lymphatics and the blood vessels. The incidence of melanoma in US is 
3.0 and in Europe it is 2.2-19.2 in 100.000 and it has been rising in the past 30 years.
[1,2] The conventional risk factors for development of melanoma are fair skin, history 
of melanoma in the index patient or their family members, having clinically atypical 
moles, sunburns and exposition to UV-radiation.[3, 4] Because the knowledge of the 
traditional risk factors has not lead to effective prevention programs it is worthwhile 
looking into alternative risk factors.[5] Atopic disorders; atopic dermatitis, hayfever and 
atopic asthma have been of interest in epidemiological studies as a risk and a protective 
factor for cancer. These studies have shown lower prevalences of different types of can-
cer in atopic individuals.[6, 7] In two cohort studies with more than 31000 patients with 
atopic eczema a decreased prevalence of MM, albeit borderline significant, has been 
found with a total of 6 and 12 melanoma patients respectively.[8,9] In three prospective 
studies children with atopic dermatitis had significantly fewer nevi which was implied 
to reduce the risk of melanoma.[10-12] On the other hand a health survey in 3.308 Aus-
tralians revealed an increased prevalence of melanoma (27 cases with hazard ratio 2.39, 
95% CI [1.00-5.70]) in men with hayfever.[13] In contrast, another German case-control 
study from 1988 with 331 melanoma patients demonstrated that melanoma patients 
were less likely to report atopic symptoms (4.2% vs. 10%). [14] The effect of asthma has 
also been assessed in a cohort of hospitalized asthmatics. The standardized incidence 
of melanoma was found to be decreased in a ten-year period in 1970s in Sweden, but 
only 72 melanoma cases occurred.[15] This was also found in another large cohort study 
of same methodology with 64 346 asthma patients.[16] However this finding was not 
consistent for all decades and was not found in patients with multiple admissions for 
asthma. These previous studies have been heterogeneous, registry-based and focussing 
on a single atopic disorder while assessing the incidences of multiple cancers simultane-
ously. From their data we can not conclude weather atopic disorders are a risk factor for 
development or progression of cutaneous melanoma.
PATIENTS ANd METHOdS
Study population
The melanoma patients were recruited from the department of Dermatology and 
Venereology of the Erasmus Medical Centre in Rotterdam. They comprised 280,Dutch, 
Caucasian patients diagnosed with a cutaneous melanoma between 2000 and 2010 
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extracted from our administrative registry. The diagnosis was histologically confirmed in 
all patients by certified pathologists. The control group consisted of melanoma patient´s 
spouses. All subjects were sent identical questionnaires concerning atopic manifesta-
tions and their treatment. Melanoma patients and their spouses were also sent a ques-
tionnaire assessing their skin phototype. The choice for this control group was made 
because of availability and because of the match in ethnic, socio-economic and external 
factors without genetic bias. Because atopic disorders are largely genetically deter-
mined and are usually seen in childhood it is not to be expected that this exposure is of 
any influence on partner choice later in life. The medical ethical committee at Erasmus 
Medical Center provides a waiver for single-subject questionnaire based studies. This 
study has been conducted in accordance with the Declaration of Helsinki.
Patient reported atopic disease and skin type
The subjects were approached through a postal survey. Non-responders were contacted 
a second time. They were sent a questionnaire comprising questions from the European 
Community Respiratory Health Survey and International Study of Asthma and Allergies 
in Children protocol.[17, 18] Subjects were considered to have asthma if they positively 
answered the question “Have you ever been diagnosed with asthma by a doctor?” and 
if the answer to question “How old were you when you were diagnosed with asthma?” 
was less than 25 years in order to prevent misclassification of subjects with chronic ob-
structive pulmonary disease. Diagnosis of atopic dermatitis was made in patients with 
eczema diagnosed by a physician, with an onset before age 25 and duration of more 
than 1 year. For diagnosis of hayfever patients had to answer next question affirmatively; 
“Have you ever had hayfever?” and they would have to have it before the age of 25. 
Because atopic disorders wane after childhood we have deemed patients diagnosed 
before the age of 25 to be atopic. This also prevents inclusion of chronic pulmonary 
obstructive disease patients as asthmatics. Also other forms of dermatitis are more likely 
after the age of 25. To assess the Fitzpatrick skin type the patients filled in the `Fitzpatrick 
skin type questionnaire.[19] This allows the comparison of the effect of atopy and a 
conventional risk factor which is a skin phototype lower than 3.
Statistics
For sample size calculations, we assumed a prevalence of 20% of atopic disorders in our 
control group, as we have found previously[20] and expected half of this proportion in 
melanoma patients.[14] For a power of 80% and an alpha level of 0.05, a sample size 
of 135 cases and 135 controls was required. The Chi-squared test was used to test for 
statistical differences in proportions. The logistic multiple regression analysis was per-
formed in standard fashion where all variables with p<0.20 from the univariate analysis 
were included. In order to be able to assess and compare the effect size of individual 
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determinants, the variables have analyses by enter method. All data were analysed us-
ing IBM SPSS version 19.0 (Chicago, Illinois 2011)
RESULTS
demographic characteristics
A total of 184(61%) Dutch melanoma patients and 169(56%) of their spouses responded 
to the questionnaire. (Table 1) The control subjects were younger (53 vs. 57 years 
p=0.001) and more frequently male (53% vs. 41% p=0.001). The family history of atopy 
did not differ across the groups. Melanoma patients had a skin phototype lower than 3 
more frequently than controls (60% vs. 36% p<0.001). The median Breslow-thickness of 
our patients was 1.1 mm [IQR 0.66-2.00]. Twenty-three of them had metastases and 29 
had a second melanoma. The two control group components did not differ with regard 
to demographic characteristics or atopic features.
Table 1. Subject characterisitcs
Melanoma patients Controls p-value
Number 184 169
Mean age (SD) 57 (14) 56 (14) 0.274
Male sex 75 (41%) 86 (51%) 0.056
Family history of atopy 95 (52%) 79 (47%) 0.359
Skin phototype < 3 108 (60%) 60 (36%) <0.001
Breslow thickness median (mm) 1,1 IQR[0.66-2.00] - -
 Metastases 23 (13%) - -
 Second melanoma 29 (16%) - -
Abbreviations: SD, standard deviation; IQR, interquartile range
Definitions: Metastases; lymphatic or distant site metastases, Second melanoma; new primary cutaneous 
melanoma
Atopic features
There were no statistically significant differences in atopic eczema, hayfever and the 
use of disease specific medication across the groups.(Table 2). Melanoma patients 
reported less frequently to have asthma but this was not statistically significant (3.8% 
vs. 8.2% p=0.075). In the univariate regression analysis the strongest association was 
found between melanoma and high risk skin phototype i.e. skin phototypes 1 and 2 
(OR 2.69, 95% CI[1.74-4.14]) (Table 3). Nevertheless, history of asthma seemed to be 
inversely associated with melanoma OR 0.44 95% CI (0.17-1.11) but this was not statisti-
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cally significant. High risk skin phototype remained the most important risk factor in the 
multiple regression analysis adjusted OR 2.60. 95% CI [1.66-4.05].
Table 2. Life time prevalence of atopic features in 184 melanoma patients versus 169 controls
Melanoma patients Controls p-value
Number 184 169
Asthma 7 (3.8%) 14 (8.2%) 0.075
Current inhalator use 7 (3.8%) 11 (6.5%) 0.249
Atopic dermatitis 16 (8.7%) 14 (8.2%) 0.890
Current topical corticosteroid use 26 (14.1%) 19 (11.2%) 0.416
Hayfever 28 (15.2%) 31 (18.3%) 0.432
Current use of antihistaminics 22 (12.0%) 23 (13.6%) 0.642
Any atopic disorder 44 (24.0%) 45 (26.6%) 0.557
Table 3. Standard uni- and multivariate regression analysis for risk of melanoma
Unadjusted OR for melanoma
with 95% CI
Adjusted OR for melanoma
with 95% CI
Age 1.01 (1.00-1.03) 1.01 (1.0-1.03)
Male sex 0.66 (0.44-1.01) 0.72 (0.46-1.12)
Skin phototype < 3 2.69 (1.74-4.14) 2.61 (1.67-4.07)
Asthma 0.44 (0.17-1.11) 0.53 (0.20-1.41)
Atopic dermatitis 1.05 (0.50-2.23) n/a
Hayfever 0.80 (0.46-1.40) n/a
Any atopic disorder 0.87 (0.54-1.40) n/a
Variables with p > 0.20 were left out from multivariate analysis. Variables with p<0.20 are printed in bold.
Abbreviations: OR; odds ratio, 95% CI; 95% confidence intervals
Atopy in melanoma patients
For the analysis of the effect of atopy on prognostic parameters of melanoma we com-
pared melanoma patients with, eczema, hayfever or asthma to patients who reported 
none of these atopic disorders. Atopic melanoma patients were younger on the average 
than the non-atopic patients (54 vs. 59 years, p=0.035) (Table 4). Nevertheless, atopic 
patients did not differ from non-atopic patients in terms of Breslow-thickness, metasta-
ses and second melanomas. However, high risk skin types were more prevalent in atopic 
patients (70% vs. 57% p=0.085). The seven asthmatic melanoma patients did not differ 
from the non-asthmatic in terms of Breslow thickness 0.9 IQR[0.4-2.4] vs. 1.1 IQR[0.7-
2.0]. Grouping the patients according to atopic dermatitis and hayfever status yielded 
essentially same results.
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Table 4. Atopic versus non-atopic melanoma patients
Atopic melanoma patients Non-atopic melanoma patients p-value
 Number of patients 44 140
Age, mean (SD) 54(14) 59(14) P=0.035
Age at diagnosis, mean (SD) 48(15) 52/(15) P=0.309
Male sex 16/44 59/140 P=0.309
Skin phototype < 3 30/43 78/138 P=0.085
Breslow thickness, median 
[IQR]
1.00 (0.51-2.02) 1.10 [0.70-2.00] P=0.722
Metastases 5/44 18/140 P=0.514
Second melanoma 8/44 21/140 P=0.384
Abbreviations: SD, standard deviation; IQR, interquartile range
Definitions: Metastases; lymphatic or distant site metastases, Second melanoma; new primary cutaneous 
melanoma
dISCUSSION
Our findings indicate that atopic dermatitis and hayfever are not a protective or a risk 
factor for melanoma. Asthma however may be associated with a lower risk of melanoma as 
found in previous studies.[15, 16] Although they were more prevalent, hayfever and atopic 
eczema did not show any association with melanoma. In comparison, having a high risk 
skin phototype was found to be significantly associated with melanoma and its effect on 
the odds ratio was much greater than the effect of having an atopic disorder. Atopic disor-
ders were also not associated with prognostic factors for melanoma like Breslow thickness 
and metastasis. Greatest limitation of our study is the low number of cases although our 
study sufficiently excludes a large effect from atopic dermatitis and hayfever. A bigger 
study is necessary to confirm the findings in patients with asthma. Also the retrospective 
setup may introduce selection bias because of the melanoma lethality. However, a case 
control methodology is preferred because of the high prevalence of atopic disorders i.e. 
exposure and relatively low prevalence of melanoma. Also, there is not a more practical 
way to ascertain atopy as it is mostly found during childhood. It is noteworthy that atopic 
melanoma patients had lower skin phototypes than non-atopic patients which is actually 
expected to increases their chance of having a melanoma. It also means that adjustment 
for skin phototype is warranted in future studies. Because of the different skin phototype 
in controls there is a possibility of different ethnicities which may also influence the preva-
lence of atopy. There is no obvious mechanism to explain how asthma may lower the risk 
of melanoma. We suggest less exposure to sun because of less outdoor activities or an 
altered immune system be looked into in future studies. Traditional risk factors for mela-
noma such as the skin phototype and number of nevi should be also taken into account 
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when assessing alternative risk factors. We believe that our study is of value for future 
investigations, suggesting a methodological approach. For now, our data to suggest that 
asthma may protect from cutaneous melanoma.
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ABSTRACT
Importance: Previous research has suggested an association between atopic dermatitis 
and coronary heart disease. These studies did not employ validated measures of cardio-
vascular disease, its risk factors and validated diagnostic criteria for atopic dermatitis 
and/or included mostly hospitalized AD patients.
Objective: The objective of this study was to assess the associations of coronary heart 
disease, its risk factors and atopic dermatitis with validated disease definitions and 
prospectively gathered, predefined data from a population based cohort.
design: We performed cross sectional analyses of the data from the prospective cohort, 
the Rotterdam Study. Multivariable models were constructed taking into account all 
traditional cardiovascular risk factors.
Setting: Population based.
Participants: Inhabitants of the Ommoord district in Rotterdam.
Exposures: Atopic dermatitis was defined according to the modified UK working party’s 
criteria.
Main Outcome Measures: The coronary heart disease status was obtained through 
prospective checks of all patients’ records, regular medical checks, laboratory and ra-
diological investigation, electrocardiograms, home interviews and municipality records.
Results: We screened 4386 subjects of whom 723 were found to have AD. There were 
63 cases of coronary heart disease in the atopic dermatitis group and 276 in the control 
group (8.7% vs 7.6%, p=0.358)
After adjusting for sex and age an OR 1.42 95%CI [1.05-1.89] was found. In the fully 
adjusted model this was OR 1.54 95%CI [1.09-2.15]. Atopic dermatitis did not associate 
positively with any of the traditional cardiovascular risk factors.
Conclusion: Atopic dermatitis in community dwelling patients is associated with 
coronary heart disease but it is this association is independent of the traditional cardio-
vascular risk factors.
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KEy POINTS
Question: Is atopic dermatitis associated with coronary heart disease in community 
dwelling patients?
Findings: Elderly AD patients are more likely to have had coronary heart disease than 
controls after adjusting for traditional cardiovascular risk factors.
Meaning: The association between atopic dermatitis and coronary heart disease is 
independent of the traditional risk factors in community dwelling patients.
ABBREvIATIONS
AD; Atopic dermatitis
CHD; coronary heart disease
CVD; cardiovascular disease
OR; Odds ratio
RS; Rotterdam study
95% CI; 95% confidence interval
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INTROdUCTION
Atopic dermatitis (AD) is one of the most prevalent inflammatory skin conditions affect-
ing up to 30% of infants and about 10% of adults and its incidence has tripled in the past 
three decades. 1Atopic dermatitis is the result of an impaired epidermal barrier, partly 
due to mutations in the filaggrin gene, combined with an overactive, Th2-polarized im-
mune system. 2
Traditionally, associated disorders i.e. comorbidities are atopic asthma, food allergies 
and allergic rhino-conjunctivitis. However in dermatology journals increasing attention 
is being given to systemic effects and cardiovascular comorbidities in patients with AD 
in parallel with extensively studied psoriasis vulgaris, another prevalent inflammatory 
dermatosis.3 From the cardiologist point of view there is a need for non-laboratory, 
clinically identifiable indicators of risk of cardiovascular disease (CVD) such as skin 
signs.4 Previous studies on this matter either used a self-reported definition of AD and 
cardiovascular risk factors, focused on risk factors rather than cardiovascular events or 
were based on administrative health insurance data and did not fully control for known 
CVD risk factors and/or included exclusively hospitalized AD patients.
In a recent U.S. population-based study by Silverberg et al, self-reported AD patients 
were found to be more likely to be exposed to cardiovascular risk factors such as smok-
ing (aOR, 1.28; 95% CI, 1.12-1.45), drinking of alcoholic beverages (aOR, 1.16; 95% CI, 
1.03-1.31), having higher body mass index (BMI) (adjusted β, 0.86; 95% CI, 0.37-1.36) 
and hypertension (aOR, 1.56; 95% CI 1.22-1.99).5 Another population-based study by 
the same team found increased prevalences of self-reported acute myocardial infarction 
(MI), angina and peripheral vascular disease (PVD) in the U.S. 6 The Nurses’ Health Study, 
also in U.S., with 78,702 participants found no association between self-reported AD 
and non-fatal MI.7 They did not report specifically on the associations between AD and 
CVD risk factors. A Taiwanese population-based study of health care administrative data 
of 20,323 AD patients showed and increased incidence rate (IR, 1.33; 95%CI, 1.12-1.59) 
of ischemic stroke compared with co-morbidity matched controls in Thailand.8 This ef-
fect was stronger in patients with severe atopic dermatitis. In contrast, in the studies of 
European populations no association between AD and CVD risk factors was detected 
according to a review from 2015.9 However, a recent study of an administrative cohort 
of 1.2 million subjects in Germany revealed an adjusted relative risk of (aRR 1.32; 95% 
CI 1.26-1.38) of angina pectoris (AP) in AD patients.10 In addition to the aforementioned 
variations in outcomes, a Danish study of administrative health care data revealed a 
protective effect of mild AD, defined as AD without systemic treatment, on coronary 
heart disease (IRR 0.73; 95% CI 0.59-0.91).11 In this study severe AD was not significantly 
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associated with coronary heart disease in age and sex and fully adjusted analyses (IRR 
1.39; 95%CI 0.95-2.03).
The objective of our study was to investigate whether AD, diagnosed with modified U.K. 
Working Party’s diagnostic criteria associates with coronary heart disease (CHD) and 
CVD risk factors within a population-based Dutch cohort (i.e. Rotterdam Study) with 
detailed and validated information available on CHD, CVD risk factors and AD. 12
METHOdS
Study design and study population
The Rotterdam study (RS) is an ongoing prospective population-based cohort study 
that follows inhabitants of the Ommoord district of Rotterdam, the Netherlands since 
1990.12 It is designed to make possible high standard research of CVD as its primary 
objective. In January 1990, the first cohort (RS-I) of 7,938 participants (78% of invitees) 
aged 55 years or older was established. In 2000, a second cohort (RS-II) was added to 
the RS, including 3,011 participants (67% of invitees) who had turned 55 years of age 
or had moved into the study district. The third cohort (RS-III) was established in 2006, 
in which 3,932 participants (65% of invitees) aged 45-54 years were added to the co-
hort. The RS reflects the population of the Netherlands in terms of co-morbidities and 
health consumption. Participants of the present study were all above 50 years of age 
and >95% are of Caucasian descent. Dermatologic screening was introduced in August 
2010. Since then, full body surface examinations (FBSE) (with the exception of the skin 
covered by socks and underwear) are being conducted by four dermatologists trained 
physicians focusing on the most common skin diseases such as skin (pre-)malignancies, 
atopic dermatitis, hand eczema, psoriasis, and varicose veins. All participants of the RS 
are dermatologically screened. The current study uses data from the extended cohorts 
comprising subjects who have been dermatologically screened. It is a cross-sectional 
analysis of the currently available RS data. The RS is approved by the Medical Ethics of 
the Erasmus MC, University Medical Center and The Netherlands Ministry of Health and 
is conducted in concordance with the Helsinki Guidelines. All participants in the study 
gave written informed consent.
Exposure: Atopic dermatitis
The participants were interviewed at home and full body surface examination (FBSE) 
was performed by dermatologist trained physicians in a medical research facility in 
the centre of the RS district between 2010 and 2015. The FBSE was structured by a 
predefined set of common dermatologic findings and their localizations such as actinic 
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keratosis, basal cell carcinoma, eczema, psoriasis etc. The research physicians as well as 
the participants were unaware of the current hypothesis. The diagnosis of AD was made 
according to the diagnostic guidelines for atopic dermatitis from the U.K. working party 
which is the most validated diagnostic tool in the clinical and investigational settings.13 
These criteria comprise one major criterion plus three or more minor criteria. ‘An itchy 
skin condition in past 12 months’ is the must have criterion and the participant needs to 
fulfil at least three minor criteria which are: ‘history of involvement of the skin creases’, 
‘a personal history of asthma or hay fever’, ‘a history of generally dry skin in the last 
year’, ‘visible flexural eczema’ and ‘onset under 2 years of age’. However, no diagnostic 
criteria of AD have been validated for adult populations such as the RS. We therefore 
made adjustments to the U.K. working party’s criteria prior to the analyses based on our 
previous publication.14 To include patients with current remission another criterion was 
added “diagnosis of eczema by a physician ever”. The personal history of other atopic 
diseases was extended with ‘house dust mite allergy’, because it is strongly related to 
atopic diseases in adults.15 Furthermore sites of visible eczema were adapted. In adults, 
atopic dermatitis also occurs on the extremities, hands and trunk.16 Finally the onset age 
was prolonged to ever instead of 2 years of age, to include patients with later onsets.16 
Thus, patients who reported having an itchy condition and who fulfilled at least 3 of the 
other 5 criteria were considered to have AD in this study. Patients who did not fulfil these 
criteria were considered unexposed.
Outcomes: CHd and Cvd risk factors
The outcomes in this study is prevalent coronary heart disease and has been described 
in detail previously.17 In short, coronary heart disease (CHD) was defined as fatal or 
non-fatal myocardial infarction, surgical or percutaneous coronary revascularisation 
procedure (as a proxy for unstable or incapacitating angina), or death from coronary 
heart disease. RS has been specifically designed with the objective of studying CHD 
comprising MI, myocardial revascularization, mortality through CHD, and heart failure. 
This is established through regular checks of medical records at the family doctor’s 
office, continuous linkage with electronic patient’s records, laboratory and radiologic in-
vestigation, electrocardiograms home interviews, hospital discharge letters, pharmacy 
prescription records, and municipality records.
Covariates and cardiovascular risk factors
We considered all traditional risk factors of CHD as covariates in our fully adjusted 
multivariable models. These are: age, sex, smoking status as assessed by multiple home 
interviews, body mass index (BMI), total serum cholesterol, serum high-density lipo-
protein, systolic and diastolic blood pressures, medication for hyperlipidemia, diabetes 
mellitus defined as use of oral glucose lowering drugs or insulin or non-fasting glucose 
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> 11mmol/L or fasting glucose >7mmol/L. Hypertension was defined as systolic blood 
pressure ≥140 mm Hg or diastolic pressure ≥90 mm Hg (mean of two measurements) or 
the use of antihypertensives. Alcohol consumption was categorized as less than 1 glass/
day, 1-4 glasses/day for men and 1-2 glasses/day for women, and > 4 glasses/day for 
men and > 2 glasses/day for women. These were all assessed prospectively on a regular 
basis. Education was assessed according to the standard classification of education com-
parable to the international standard classification of education and was grouped into 
four categories “elementary education”, “lower secondary education”, “higher secondary 
education” and “tertiary education”
Statistical analysis
On the basis of previous study which found a prevalence of MI of 6.0% in AD patients 
vs. 2.4% controls and prevalences of class I and II obesity (BMI>35) 14.6% vs. 10.9% a 
sample size needed for a power of 80% and an error rate of 5% was 609 AD patients and 
1217 non-AD subjects. Complete data analysis was performed for all variables exclud-
ing subjects missing the exposure or the outcome. Primary analyses were performed 
by binary logistic regression. In order to detect possible confounders and their effect 
on the AD/CHD association, two-way binary logistic regression was performed. Covari-
ates with a p<0.20 effect on the AD-CHD association were added to the main models. 
In the main analyses three multivariable models were constructed and used to detect 
associations between AD (dependent variable) and the presence of CHD (independent 
variable). First model was adjusted for age and sex. Second model was additively ad-
justed for possible confounders from the two-way analysis and for cardiovascular risk 
factors differing across groups. The third model was adjusted for all known CVD risk 
factors mentioned under covariates. Sensitivity analysis was carried out on separate AD 
criteria in order to assess the contribution of the various components atopic dermatitis 
and to test how changes in definition of AD influenced the association. This makes the 
results more comparable to previous studies which used different definitions for AD. 
Also, AD being a diagnosis made by fulfilment criteria it is possible that a detected as-
sociation is driven solely by one criterion and not the diagnosis of AD while a significant 
number of individuals are expected to fulfil some but not all necessary criteria, creating 
a category between exposed and unexposed. To reduce this contamination we also 
included an analysis in which the control consisted of subjects who explicitly never had 
been diagnosed with any form of eczema. Values of p<0.05 were considered significant. 
All data were analyzed using IBM SPSS 21.0 and R ver. 3.1.3, except for the sample size 
calculation; PS Power and Sample Size Calculations Version 3.0.
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RESULTS
Patient characteristics
 An FBSE was carried-out in a total of 4,386 participants but information concerning CHD 
and its risk factors was available for 4,342 (figure 1). Seven hundred twenty-three (16%) 
individuals were diagnosed with AD according to the criteria (table 1). These individuals 
reported having asthma, hay fever or house dust mite allergy more frequently than non-
AD subjects (47% vs. 13%). Of these 723 subjects, 37% had a history of flexural involve-
ment while only 5% had visible flexural dermatitis/eczema on examination (table 1) and 
26% had any visible dermatitis. Hand eczema was the most prevalent form of visible 
eczema (hand eczema 13%, eczema on the extremities 12%, flexural eczema 5% and 
truncal eczema 4%). Of all AD cases 75% where already diagnosed with eczema by their 
family doctor or a dermatologist while this percentage was 13% in non-AD subjects.
Rotterdam Study
N=14926
Continuous monitoring for risk factors and cardiovascular events
Subjects dermatologically screened
N=4386
Cardiovascular data not
available at the time
N=44
STUDY POPULATION
N=4342
Non-AD subjects
N=3619
AD patients
N=723
Included in data anlysis
of coronary heart disease and its risk factors
Ongoing dermatologic
interviewing and skin 
examination
Excluded
Included
Meet AD 
criteria
Do not meet 
AD criteria
Figure 1. Flow diagram of the study population
A part of the Rotterdam Study population has been dermatologically screened and comprises the current 
study population
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Table 1 Subject characteristics
Ad
N=723
No Ad
N=3619
Ad criteria
Major criterion Itchy skin condition 723 (100%) 1331 (37%)
Minor criteria
 History of asthma 107 (15%) 148 (4%)
 History of hay fever 215 (13%) 278 (8%)
 History of HDM allergy 141 (20%) 192 (5%)
 History of any of the above 339 (47%) 482 (13%)
 History of involvement of skin creases 265 (37%) 246 (7%)
 Generalized xerosis cutis on
 examination 640 (89%) 2352 (65%)
 Visible dermatitis 198 (27%) 153 (4%)
 Diagnosed with eczema by a physician 545 (75%) 471 (13%)
Other findings
 Physician diagnosed eczema before the age of 12 155 (21%) 121 (3%)
 Visible dermatitis in creases 38 (5%) 17 (1%)
 Visible hand dermatitis 96 (13%) 95 (3%)
 BSA (mean) 0.52% 0.08%
Atopic dermatitis related findings in AD and non-AD subjects
Ad and Cvd risk factors
Atopic dermatitis patients were slightly younger (67.5 vs. 68.5 p=0.003) and less fre-
quently male (37% vs 45% p<0.001). They also had slightly lower mean systolic blood 
pressure (142.3 vs 144.4)) and a higher mean HDL level (1.52 vs 1.48). No other statisti-
cally significant differences concerning the CVD risk factors were observed.
Ad and CHd
There were 63 unique cases of CHD in the AD group and 276 in the non-AD group (8.7% 
vs. 7.6% p=0.358; table 2). The association between AD and CHD was significantly altered 
only by age, sex and HDL cholesterol in the bivariate analysis of confounders (table 3). 
A diagnosis of AD was not associated with CHD in the crude analysis OR 1.16; 95% CI 
(0.86-1.53) table 4.
After adjusting for sex and age in the first multivariate model a statistically significant 
association was found OR 1.42; 95% CI (1.05-1.89). This remained essentially unaltered 
in the second and third models with OR 1.42; 95% CI (1.04-1.90) and OR 1.54; 95% CI 
(1.09-2.15) respectively.
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Table 2. Cardiovascular risk factors in AD patients and controls.
CHd risk factors Ad n=723 No Ad n=3619 p-value
Age (years) 67.5 ± 8.6 68.5 ± 8.5 0.003
Sex (male) 266 (37%) 1552 (45%) <0.001
Sys. blood pressure 142.3 ± 21.6 144.4 ± 22.0 0.038
dias. blood pressure 83.6 ± 11.1 84.1 ± 11.2 0.219
Antihypertensive treatment 335 (46%) 1717 (46%) 0.684
diuretics 112 (16%) 528 (15%) 0.571
BMI 27.7 ± 4.5 27.6 ± 4.4 0.475
Total cholesterol (mmol/L) 5.48 ± 1.10 5.47 ± 1.12 0.941
HdL (mmol/L) 1.52 ± 0.44 1.48 ± 0.43 0.013
Cholesterol lowering drugs 208 (29%) 1147 (30%) 0.444
diabetes mellitus 106 (15%) 565 (15%) 0.918
Current smoking 97 (13%) 575 (16%) 0.105
Alcohol use 174 (24%) 868(24%) 1.000
CHd 63 (8.7%) 276 (7.6%) 0.358
Education 0.470
 Elementary 79 (11%) 472 (13%)
 Lower secondary 285 (39%) 1411 (39%)
 Higher secondary 209 (29%) 1018 (28%)
 Tertiary 150 (21%) 718 (20%)
Means and SD and percentages are reported where appropriate.
BMI, body mass index; HDL, high density lipoprotein; CHD, coronary heart disease
Table 3 Potential confounders
Ad adjusted for OR (95% CI) of CHd p-value
No adjusting 1.16 0.86 1.53 0.320
Age 1.23 0.91 1.63 0.166
Sex 1.31 0.97 1.75 0.069
Current smoking 1.15 0.86 1.52 0.331
BMI 1.15 0.86 1.52 0.336
Total cholesterol 1.19 0.88 1.61 0.253
HDL cholesterol 1.25 0.93 1.65 0.138
Hypertension 1.19 0.88 1.58 0.240
Diabetes 1.16 0.86 1.54 0.311
Alcohol use 1.16 0.86 1.53 0.321
Education level 1.17 0.87 1.54 0.294
Use of antihypertensives 1.15 0.85 1.53 0.364
Use of diuretics 1.17 0.87 1.54 0.295
Left column contains potential confounders of the AD-CHD association and the middle the effects
expressed as odds ratio
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Sensitivity and subgroup analysis
In a sensitivity analysis we investigated the contribution of the individual AD criteria 
to the AD-CHD association. Of the individual criteria for AD only generally dry skin was 
significantly associated with CHD with adjusted ORs of 1.31; 95% CI (1.01-1.71) for model 
, OR 1.31; 95% CI (1.01-1.72) for model 2 and OR 1.34; 95% CI (1.00-1.81) for the fully 
adjusted model (table 4).
Table 4. The association between AD, components of AD diagnosis and CHD.
variable Crude
OR (95% CI)
Model 1
OR (95% CI)
Model 2
OR (95% CI)
Model 3
OR (95% CI)
diagnosis of Ad 1.16 (0.86-1.53) 1.42 (1.05-1.89) 1.42 (1.04-1.90) 1.54 (1.09-2.15)
Ad criteria tested separately
 Itch 1.02 (0.81-1.27) 1.14 (0.91-1.43) 1.13 (0.90-1.43) 1.19 (0.92-1.54)
 Involvement of skin creases 0.80 (0.54-1.14) 0.97 (0.65-1.40) 0.97 (0.65-1.41) 0.99 (0.64-1.50)
 Asthma, hay fever or house dust
 mite allergy 0.88 (0.65-1.17) 1.17 (0.86-1.57) 1.18 (0.86-1.60) 1.20 (0.84-1.68)
 Generally dry skin 1.40 (1.09-1.82) 1.31 (1.01-1.71) 1.31 (1.01-1.72) 1.34 (1.00-1.81)
 Visible dermatitis 0.82 (0.51-1.24) 0.80 (0.50-1.24) 0.83 (0.51-1.28) 0.98 (0.58-1.58)
 Diagnosis of eczema by physician 0.99 (0.88-1.09) 1.00 (0.89-1.10) 0.99 (0.88-1.09) 1.04 (0.91-1.16)
 diagnosis of eczema before age 
of 12
0.95 (0.59-1.36) 1.20 (0.74-1.72) 1.27 (0.78-1.86) 1.34 (0.78-2.07)
diagnosis of Ad with Previous 
eczema diagnosis excluded from 
controls
N=3326
1.46 (0.85-2.36) 1.75 (1.00-2.90) 1.86 (1.06-3.10) 1.80 (0.96-3.25)
Model 1 adjusted for sex and age;
Model 2 adjusted for age, sex and HDL; (continued)
Model 3 same as model 2 with diastolic blood pressure, use of antihypertensives, BMI, total cholesterol, 
cholesterol lowering drugs, diabetes mellitus, alcohol use, smoking and education level
Exclusion of individuals who were ever diagnosed with any eczema from the control 
group increased the ORs but was only statistically significant in model 1 and 2 OR 1.75; 
95% CI (1.00-2.90) and OR 1.86; 95% CI (1.06-3.10).
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dISCUSSION
The findings in our study suggest an association between CHD and AD which is 
independent of the traditional CVD risk factors such as smoking, obesity, high blood 
pressure and hypercholesterolemia with OR 1.42 95%CI [1.05-1.89]. Our findings are 
in concordance with the effect size found in a recent large prospective German study 
(aRR 1.32 vs. aOR 1.42).10 In contrast to the studies from the U.S. and Asia we found no 
association between AD and traditional CVD risk factors.9,18 This can be explained by the 
method of measuring of the risk factors and the use of a European study population. 
In previous studies the exposures were patient-reported while our study presents data 
obtained through validated methods. Supporting this notion is that in the same cohort 
of NHANES (National Health and Nutrition Examination Study) an inverse association 
between specific serum IgE and MI was found by Jaramillo et al. while Silverberg et al 
reported higher odds of having CVD and congestive heart failure in patients reporting 
flexural eczema. 6,19 This however, may also suggest that the increased risk of CVD in AD 
patients is in fact atopy independent and not driven by systemic inflammation. The sci-
entific community is currently divided according to two main hypotheses explaining the 
associations found between CVD and AD. The first hypothesis is based on confounding 
by traditional CVD risk factors promoted by yet another study by Silverberg et al which 
in addition proposes that the increased risk of CVD in AD patients is attributable to a sed-
entary life style and sleep disturbances due to nightly itching. The second hypothesis is 
inflammation dependent, based on animal models, and states that AD leads to systemic 
inflammation and therefore enhanced atherosclerosis. 3,5,20,21 We were not able to assess 
the physical activity in our subjects but itch per se seems not to be associated with CHD 
in our study population. A more recent, well conducted study has demonstrated that 
adult AD patients in the U.S. lead a more sedentary life style than controls which may 
explain the increased risk of CVD.22 We were however unable to reproduce the results 
from the high impact study by Silverberg et al when using the same definition of AD 
(patient reported physician’s diagnosis).5 In support, no positive association was found 
in underlying molecular pathways, between AD and CVD in terms of genetic risk variants 
and metabolomics in the aforementioned German study of multiple large prospective 
cohorts.10
On the other hand there is recent evidence from mouse models that acute disruption 
of the epidermal barrier by tape stripping or chronic disruption by aging lead to an in-
crease in serum cytokines (IL-1α, IL-1β, IL-6, TNF-α) and amyloid A and that this systemic 
inflammation is reversible upon restoration of the barrier with topical petrolatum.23 The 
finding that general xerosis cutis associates most significantly with CHD in our cohort 
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may have a basis in the same mechanisms and may be the pathophysiological bridge 
between AD and CVD.
The RS has been designed as a population-based cohort with the main objective be-
ing the epidemiological investigation of CVD minimizing residual confounding while 
the ascertainment of the outcome is standardized and limits misclassification bias. The 
fact that we analyzed hard outcome data on CHD rather than subclinical measures 
guarantees that there is no effect of increased detection of outcome from AD-status. 
Furthermore, the AD patients underwent the same examinations as the reference popu-
lation excluding selection and detection bias while the diagnosis of AD has been made 
in accordance with validated UK working party’s criteria. This is also the first study on AD 
and CHD where AD has been defined with a validated diagnostic tool. As these criteria 
were adapted some misclassification is possible. It would however lead to a dilution of 
the effect observed favoring the null hypothesis. Dowlatshahi and colleagues found an 
association between psoriasis vulgaris and CVD risk factors such as obesity, smoking and 
hypertension in this very same cohort.24 This is in concordance with the data available 
from the literature and adds validity to our methods. The group that met the AD criteria 
comprised 16 % of the total study population. This is comparable to the prevalence of 
AD in children from the 40’s and 50’s (childhood period in our study population), as 
described in literature.25 This is a cross-sectional study on prevalence of CHD, as such 
it carries with it some limitations and no causal relation can be inferred from the as-
sociations found. The age of onset of AD being a disease of childhood is much younger 
than the onset of CVDs. This makes it hard to study the association within a prospective 
cohort. The RS population is older than 55 years and may not represent the average AD 
patient, especially those with severe disease or systemically treated and hospitalized 
patients. In addition the findings are not generalizable to individuals younger than 55 
years of age, a group which has been demonstrated to carry the greatest excess CVD 
risk in psoriasis. Moreover, there is a possibility of survival bias in this elderly population. 
Furthermore, the duration of AD exposure could not be measured and the increased risk 
of CHD can be argued to be present only during flare ups of this episodic skin condition. 
No data on flare ups and AD treatment were available but could have made possible 
further stratification of AD patients.
The clinical significance of our findings is not fully clear. Nevertheless, AD does not seem 
to be a good independent predictor of CHD as the crude analysis showed non-significant 
findings. Research into comorbidities should eventually lead to preventative measures 
but current CVD prevention programs revolve around curbing of the traditional risk 
factors.26 It seems, from our and previous studies that the traditional risk factors do not 
seem to play a role in the AD-CVD association. Therefore, standard ways of screening will 
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not suffice a priori. What treatment should eventually be prescribed to AD patients at 
risk of CVD is one more scientific step further away. Measures of clinical relevance such 
as excess risk and number needed to screen should also be central in order to assess the 
clinical relevance of the study findings.
In conclusion, there seems to be an association between CHD and AD but this is not 
explained by traditional CVD risk factors. When considering all data available from cur-
rent research there is clear inconsistency in findings. This indicates that the AD-CHD 
association may be a spurious one or at best a phenomenon of specific subgroups. 
Future studies should focus on prospective methodologies taking into account disease 
flare-ups and severity, the treatment, physical activity and sleep disturbances. Increased 
risk of CVD in AD is probably attributable to subgroups of more severe AD patients.
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ATOPy
The best definition of atopy for clinical purposes is a predisposition towards the develop-
ment of atopic asthma, hay fever, food allergies and atopic dermatitis (AD). Therefore atopy 
is a spectral diathesis and an individual with any of the aforementioned conditions can 
be considered to be atopic to a certain degree. The best biomarker for general atopy is 
the specific serum IgE.1,2 However, increased specific IgE levels are not always found in all 
asthma and AD patients as aspecific triggers also play a role.1,3 Hence, in these disorders 
clinical criteria are needed to diagnose atopy. The most clinically and scientifically useful 
criteria to diagnose AD are the UK working Party’s Criteria.4 The pathogenesis of atopic 
disorders is most likely initiated by a skin barrier defect which is compensated for by 
the adaptive immune system leading to an activation of the T-helper lymphocyte 2 axis 
(Th-2 axis).5 The systemic spread of this Th-2 polarization has been well documented 
and manifests itself as the atopic march and leads to the development of food allergies, 
hay fever and asthma.6-8 The Th-2 mode of operating of the immune system is normally 
directed towards antigen (mainly macro-parasites) and toxin expulsion as well as barrier 
maintenance. The activation of this system in the absence of harmful antigens is called 
atopy. The overactivation of the Th-2 system in atopy is unique among immunologic 
disorders as it manifests itself in terms of behavior as sneezing (hay fever), coughing 
(asthma), vomiting (food allergies) and scratching (AD). Atopy-induced physical changes 
in the human body are hypertrophy of the mucosa and the skin and an increased secre-
tion of mucus and tears. Given the barrier-based basis of atopy, it is not surprising that all 
components of the atopic diathesis take place at the border between the body and the 
external world, i.e. the mucosal and skin surfaces. Atopic patients are thus individuals 
in whom the barrier-based defenses have failed and in whom the hierarchically higher 
innate and adaptive immune responses have been overactivated.9 As such, they are 
potentially at risk for other diseases, i.e. comorbidities, in which these parts of bodily 
defenses play a role. Next we will explain how atopy may predispose or even protect 
against other diseases as hypothesized at the beginning of this project.
Multiple SNPs (single nucleotide polymorphisms) have been shown to contribute to the 
development of overt clinical disease in the pathophysiological chain of atopy (FLG, IL4, 
IL4RA, SPINK5, CMA1, IL13, RANTES, CD14, DEFB1, GSTP1, IL18, NOD1 and TIM1).10 The 
barrier-associated genes and genes associated with leukocyte and cytokine functions 
are most frequently affected.11-13 The diminished barrier function invariably predisposes 
to a heavier exposure to toxins as well as to physical and infectious agents. At the same 
time the general and systemic polarization of the immune system towards a more Th-
2-like profile affects the normal functioning of the immune system. Traditionally this 
is attributed to the Th-1 inhibiting effects of the Th-2 polarized immune system (see 
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introduction).14 Therefore one of our hypotheses was that the impaired skin barrier of 
AD may predispose to UV-induced skin cancers and actinic keratosis (AK). In addition, 
we speculated that the Th-2 polarized immune system of atopic patients likely impairs 
the responses directed against tumors through the antagonism of the Th-1 axis, which 
also could lead to more skin cancer and AKs in AD patients (figure 1). The basis for this 
hypothesis was the idea that the general coordination of anti-tumor activity by the im-
mune system is fully executed by the Th-1 axis. In line, the Th-1 cytokines IL-2 and inter-
feron are the only cytokines efficacious in, and registered for the treatment of cancers.15 
However, IL-2 has pleiotropic effects beyond the domain of the Th-1 axis, illustrated 
by the fact that this cytokine stimulates B-cell proliferation and is even necessary for 
the proliferation and differentiation of Th-2 lymphocytes. These findings indicate the 
existence of more sophisticated effector functions of the Th-axes than explained by the 
traditional Th-1/Th-2 paradigm. 16,17 Moreover, the positive effect of IL-2 on the metasta-
sized melanoma seems to be conveyed by a Th-2 cytokine, namely IL-24.18,19 In addition 
to this apparent immunologic paradox, the association of AD with melanoma, kerati-
nocyte cancer and actinic keratosis had not been tested in a population-based sample. 
We therefore set out to account for these shortcomings. The Th-1/Th-2 paradigm, and 
AD Atopy
IL-4
IL-13
Barrier dysfunction
PSO, PSA
AK, KC, MM
CHD
Th-2 polarization
CVD risk factors
Diminished UV barrier
Unknown effect 
on B cell 
population
?
Figure 1. The hypotheses and their presumed mechanisms at the outset of the project
AD, atopic dermatitis; AK, actinic keratosis; CHD, coronary heart disease; CVD, cardiovascular disease; KC, 
keratinocyte cancer; MM, melanoma
111
General discussion
5
more specifically the antagonism between Th-1 and Th-2 cells, have also been implied 
in the inverse associations found between atopy and inflammatory disorders, which are 
traditionally categorized as Th-1 driven diseases.14 New discoveries in the past decade 
have shown a far more intricate adaptive immunological network with new Th-axes 
such as the T-regs, Th-9, Th-17 and Th-22, casting doubt on the universal applicability 
of the Th-1/Th-2 model. 20-24 Although the antagonism of the Th-1 and Th-17 systems by 
atopy has been demonstrated in rheumatoid arthritis and cutaneous psoriasis on tissue 
level, it has not been investigated in large patient cohorts of psoriasis vulgaris (PSO) and 
psoriatic arthritis (PSA).14,25 Therefore, one of the objectives was to explore how atopy 
may affect the closely related autoinflammatory disorders of PSO and PSA, because both 
diseases are traditionally regarded as Th-1 and Th-17 mediated disorders (figure 1).26,27 
Another focus of this research was the effect of the Th-2 polarization on B-lymphocytes. 
Th-2 cells are known to induce isotype switching towards IgE producing in B-cells.28,29 
However the effects of atopy on the numbers of peripheral B-cells are unknown (figure 
1).
Besides the associations between atopy with cancer and inflammatory disorders, there 
is increasing evidence linking atopy, more specifically AD, to systemic inflammation 
and cardiovascular disease (CVD).14,30 The association between CVD and AD is currently 
explained by either the presence of traditional CVD risk factors in the AD patient or by 
the effects of systemic inflammation caused by AD. However, the evidence supporting 
the association between CVD and AD is poor. Previous research presented with several 
caveats such as the use of self-reported AD, CVD risk factors, and hospitalized AD pa-
tients, while CVD caused by systemic inflammation has not been robustly demonstrated 
in humans. 31,32 The main objective of this thesis was to explore the effects of atopy on 
the prevalence and severity of selected non-atopic diseases in the domains of oncology, 
immunology and cardiovascular disease.
FINdINGS
Atopy and inflammatory disorders
In the first part of chapter 2 the focus was on atopy and PSO. Although the pathogenesis 
of PSO shows multiple defects in the epidermal barrier formation, much like in AD, its 
occurrence shows no association with asthma, hay fever, or sensitization in our study.33-35 
We therefore conclude that atopic disorders are not a likely comorbidity of PSO, nor do 
they precede the development of PSO. Another conclusion that we came to is that atopy 
does not protect from the acquisition of PSO either. However, the results in patients 
with PSA were different, as we found a lower prevalence of atopy in this population. This 
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possibly indicates a protective effect of atopy on PSA through immunologic antagonism 
between atopy, which is a Th-2 dominated inflammatory response, and PSA, which in 
turn is a Th-1 and Th-17 skewed disease (figure 2). Because clinical atopy occurs much 
earlier in life than PSA, a reversed causality is not likely. Though in case of serological 
atopy (i.e. increased specific IgE), suppression of IgE secretion later in life in PSA patients 
cannot be ruled out. Despite the fact that PSO is also Th-1 and Th-17 driven, we found no 
inverse association of PSO with asthma, hay fever and sensitization. On the level of skin, 
the antagonism between AD and PSO has been well demonstrated however.25 It is pos-
sible that in PSA patients, immunologic abnormalities are more systemically spread and 
play a greater role than the more localized cutaneous inflammation in PSO.36 It is known 
that in PSA the expression of IL-17 is most dominant, while in PSO IL-22 is the most 
abundant and most active cytokine on tissue level. 37 This would make the antagonism 
by the Th-2 axis at a systemic level possibly more relevant in PSA compared to PSO. 
Polymorphisms in the interleukin-4 (IL-4) gene probably play a role in this phenomenon 
as this Th-2 cytokine is the main antagonist of theTh-1 and Th-17 axes.38,39 Underscoring 
this theory, IL-4 has shown therapeutic value in clinical trials of PSO which was produced 
by IL-23 and Th-17 selective antagonizing effects.40-42 In a genetic study, more severe, 
erosive PSA was associated with the IL-4 receptor 150V single nucleotide polymorphism 
(SNP).43 Unfortunately, as pharmaceutical development of a non-patentable agent is not 
economically favorable, the effects of IL-4 on PSA have not yet been studied in clinical 
trials.
Atopy
? IL-4
Low IgM memory B-cells
Suppression of secretion
and functionality of 
IL-17 and IL-23
Increased susceptibility
to bacterial infections
Lower prevalence of and
less severe psoriatic
arthritis
Figure 2. Atopy and the immune system, insights from this thesis and possible pathways
The second part of this chapter focused on the pathophysiology of AD and the role 
of the B-cells therein. AD pathophysiology can be appreciated as initially an immune 
deficiency of the innate immune system (epidermal barrier dysfunction), which is fol-
lowed by changes in the adaptive immune system. However, not all cells of the adaptive 
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immune system are fully mapped in AD. The importance of the B-cells in AD has not 
been investigated with nearly half the intensity as the role of the T-lymphocytes. This 
is surprising as B-cells produce IgE, which is the hallmark protein and a biomarker of 
atopy. The IgE antibodies of AD patients have lower numbers of somatic mutations and 
antigen selection seems to play a less crucial role than in asthma and hayfever patients.44 
Still, most types of B-cells are relatively increased in the peripheral blood of AD patients. 
There is a systemic expansion of transitional and chronically activated CD27+ memory, 
plasmablasts, and IgE-expressing memory B-cell subsets and there is aberrant immuno-
globulin class switching.45,46 Previous research has also shown increased levels of CD27+ 
IgE memory cells with increased numbers of somatic hyper mutations.47,48
In chapter 2, part 2 we have demonstrated decreased absolute numbers of IgM-only 
memory B-cells in patients with AD. IgM-only memory B cells form the smallest com-
partment of B cells in the peripheral blood (about 10%) and selective IgM deficiency 
is associated with allergy and bacterial infections.49 It is not clear whether decreased 
numbers of IgM memory B-cells play a role in the pathogenesis of AD or if they are an 
epiphenomenon resulting from constitutional immunological changes in atopy (figure 
2). It is unlikely that this finding relates directly to Th-2 effects as IgM memory cells are 
T-cell independent.50 Further exploration of B-cell abnormalities in AD patients is war-
ranted with extensive AD phenotype specification and correlation with disease course 
details such as staphylococcal superinfections, eczema herpeticum and molluscum 
contagiosum infections.
Atopy and cancer
The controversial relationship between atopy and cancer has been the subject of many 
observational studies.51 Most of these studies have focused on the relationship between 
asthma and internal malignancies, showing mostly inverse associations.52,53 We have 
investigated the atopy-cancer link focusing on skin cancer and AD because both are 
primary cutaneous conditions. We hypothesized that epidermal barrier dysfunction and 
Th-1 suppression seen in AD skin could predispose to more UV-induced damage in the 
keratinocytes, subsequently leading to an increased risk of skin cancer and actinic kera-
tosis (AK) in these patients.54 Our findings disproved this hypothesis. Following this we 
concluded that increased surveillance for keratinocyte skin cancer in all AD patients is 
not warranted. Moreover, we found less severe AKs in community dwelling patients with 
AD. The case is obviously different for chronic severe AD patients who have been treated 
by UV-therapy and systemic immunosuppressants like ciclosporin A and azathioprine, 
which are known risk factors for AK and keratinocyte skin cancers.55,56
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In the second study of this chapter focusing on melanoma and atopy, we found pre-
sumptive evidence of a protective effect of asthma against melanoma. There was a 
statistical power problem as only 184 melanoma patients could be recruited from our 
university hospital center, but several other cohort studies have corroborated our find-
ings on this inverse association. 57-59 The low number of subjects was due to the fact that 
these patients, when diagnosed with melanoma, are mostly treated as soon as possible 
in non-academic hospitals and are therefore not referred to our institution. In conjunc-
tion, survivor bias could not be ruled out in this study. This may mean that the reduced 
prevalence of asthma we found in melanoma patients could be explained by the null 
hypothesis, if atopy were to confer a worse survival in melanoma.
The debate on atopy and cancer relationship has still not been settled however, which is 
probably due to the biologic heterogeneity of cancer. For example, melanoma and kera-
tinocyte carcinomas are biologically different entities though both arise in the skin and 
both are called skin cancers. A second complicating factor in the studies is the consider-
able variation in how atopy is defined. Because of these issues, multiple mechanisms 
may be at play and the effect of atopy may therefore vary in different cancers. There are 
multiple, not mutually exclusive hypotheses explaining the antagonism between atopy 
and cancer (figure 3). Atopy seems to be especially protective for melanoma, pancreatic 
carcinoma, glioma and adult acute lymphoblastic leukemia according to a review from 
2016.60 Parts of the possible mechanism have also been revealed and can be divided into 
effects encountered within the innate and the adaptive immune systems. There are mul-
tiple components within the innate immune system which counteract carcinogenesis 
and are enhanced in atopy. Such innate immune mechanisms may therefore be respon-
sible for the inverse association between atopy and cancer. The first hypothesis is only 
applicable for carcinomas i.e. epithelial malignancies. It states that, as IL-13 regulates 
the barrier repair by controlling keratinocyte maturation, its function is the clearance 
of tumor cells, toxins and carcinogens.61 Knock-out models of IL-13 show an increased 
susceptibility to carcinogenesis due to an augmented cellular differentiation.62,63 IL-13 is 
an important, well characterized and systemically increased (in atopy) cytokine belong-
ing to the Th-2 axis. Thymic stromal lymphopoietin (TSLP) may enhance these tumor 
clearing effects of IL-13.64 The second mechanism is the antagonism of the Th17 axis 
cytokines IL-6, IL-17, IL-21, IL-23 and TNF-α by the atopic Th-2 polarized immune system. 
These cytokines help build a tumor protective microenvironment and are key players 
in the propagation of carcinogenesis.65 Lower levels of the Th-17 signature cytokines, 
as is the case in atopy, help to curb the tumor growth. Adding further evidence to the 
beneficiary effect of Th2 polarization is a recent study which found a positive correla-
tion between serum eosinophils and median survival in advanced melanoma (35 vs. 
16 months).66 The reverse is true for the serum neutrophil numbers which are the Th-17 
115
General discussion
5
innate immune system counterparts of the Th-2 driven eosinophils.67 The eosinophils 
are not just bystanders but are proven to actively exert tumor rejecting activities such 
as guiding of CD8-positive T cells, macrophage polarization and tumor vasculature 
normalization.68,69 On the adaptive side of the immune system multiple hypotheses 
have also been formed. SNPs of the low density lipoprotein related protein 1B (LRP1B) 
and interleukin-12 receptor A (IL12RA2) are associated with an 60% decreased risk of 
pancreatic cancer 70,71 LRP1B is involved in fat metabolism and antigen presentation. 
LRP1B-deficient macrophages are implied in progression of cancer while the aforemen-
tioned SNPs are also associated with asthma.72,73 Several B-cell associated mechanisms 
exist in tumor immunology. B-cells are also key players in atopy and the adaptive im-
mune system in general. The first aberration in of B-cells involved in these mechanisms 
is the attenuated activity of B-regulatory cells (B-regs) in atopy.74 B-regs are known to 
infiltrate various tumors and diminish the activity of T-effector cells, natural killer cells 
and tumor-associated macrophages.75 The dysfunctional B-regs in atopic individuals 
may be less tumor protective than in non-atopic individuals.76 The second B-cell defect 
is the deviant class switching towards IgE instead of the classical progression to IgG4. It 
is currently known that tumor cells tend to shift the immune system in their microen-
vironment towards class switching to IgG4.77 IgG4 is found in the microenvironment of 
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Figure 3. Links between atopy and cancer
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melanoma and is associated with worse prognosis.78,79 Increased levels or functionality 
of IL-4 and IL-13 in atopic individuals prevent the development of this tumorigenic im-
munoglobulin by enhancing the class switching towards IgE.28 An additional hypothesis 
involves yet another recently discovered function of the IgE molecule. Dendritic cells 
are able to cross-present (using MHC 1 instead of MHC 2) tumor antigens through the 
high affinity FC receptor of the IgE (FcƐRI). This leads to enhanced activation of cytotoxic 
T-cells and increased protection against tumors.51,80 Interestingly, cross-presentation 
plays a major role in the immunity specifically against melanoma, pancreatic cancer and 
brain tumors.81,82
In the age of great advancements in immuno-oncology, research into the associations 
between atopy and cancer at any rate offers a better understanding of the immunologic 
mechanisms involved in carcinogenesis and tumor suppression. In best case, this knowl-
edge may lead to enhancements of current immunologic therapies such as vaccines 
made to interact with FcƐRI receptor and induction of anti-tumor IgE antibodies.
Atopy and cardiovascular disease
The results of our study on the possible association between CHD and AD show that 
older, community dwelling patients with AD are more frequently affected by CHD than 
non-AD subjects. This relation seems to be independent of the traditional risk factors of 
CVD such as smoking, high BMI, diabetes mellitus and hypertension. This is in contrast 
to the previous studies performed in the United States and Asian countries, showing 
an association with traditional risk factors, but in agreement with the European stud-
ies.30,83 Our results therefore indicate that if CVD is a direct comorbidity of AD it cannot 
be screened for by current methodologies (performed by the primary care physicians 
in the Netherlands) consisting of history taking and blood tests.84 The main problem in 
current CVD-AD research is the selection of an appropriate, representative study popula-
tion. Working with administrative data from non-medical databases and/or inclusion of 
hospitalized AD patients introduces misclassification and selection bias jeopardizing the 
external validity.85 Hospitalized patients are more likely to be less adherent to both AD 
and CVD medication and they are more likely to undergo diagnostic procedures leading 
to detection bias. In our study, selection (indication) bias was minimized by the use of a 
community-based cohort in the Rotterdam study. In addition, known confounders were 
accounted for before data collection and during the analysis. One of the limitations in 
the ascertainment of atopic diseases is that the diagnosis of AD had been made during 
the adult life in all our subjects which allowed introduction of recall bias in the question-
naire based variables. Ideally, the diagnosis of atopy should be made during childhood 
as atopic disorders are then most prevalent. This helps to capture as many subjects as 
possible and avoids misclassification bias.
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 As to what explains the found association between AD and CHD, two theories are 
currently adhered to by the scientific community (figure 4). The proponents of the first 
theory argue that like in psoriasis, systemic inflammation of AD could accelerate athero-
sclerosis.86 Although there is some evidence that AD may engender systemic inflamma-
tion in terms of increased serum levels of eosinophils, E-selectin and IgE, no study has 
explained the presumed mechanism by which systemic inflammation should lead to 
CVD.87 Moreover, a direct comparison of genomic and metabolomic data of CVD and AD 
patients did not reveal any overlap.88 The second theory is from a recent well conducted 
study which has shown that AD patients are more likely to live a sedentary life style and 
are less likely to engage in vigorous physical activity. Low physical activity is associated 
with an increased risk of CVD.89 Sweat and exercise are known to exacerbate AD and 
induce itch and eczema affecting hands and feet; therefore patients with AD can be lim-
ited in their physical activities. In the same line of thinking, fatigue resulting from sleep 
disturbances may affect the incentive to exercise but could also independently increase 
the risk of CVD.31,32 Behavioral adaptations in AD leading to an increased CVD risk should 
be explored further with the purpose of development of preventive programs. Currently 
the data on the subject of the AD-CVD association are too inconsistent which probably 
points out that a potential association does not stem from true pathophysiological 
mechanisms. Therefore, the contemporary evidence is insufficient to call for adjust-
ments of clinical procedures or an increase in the surveillance for CVD in AD patients.
AD
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Behavioral
adaptations
Systemic
inflammation
Traditional CVD risk 
factors
Pruritus when sweating
Nightly pruritus
Psychological burden
Less physical activity
Sleep disturbance
Depression
IgE
Eosinophils
E-selectin
Figure 4. Putative theories explaining the association between CVD and AD.
AD, atopic dermatitis; CVD, cardiovascular disease
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CONCLUSION: A NEW MOdEL OF COMORBIdITy IN ATOPy
It is clear that our observations are based on various biologic mechanisms and that 
researchers should account for the different types of associations between diseases in 
future studies. When studying the co-occurrence of diseases one of the first questions 
which come into mind is whether the association found is based on causality or if it is 
a product of bias and chance. Discerning the two helps to understand the relevance of 
the research at hand. However, co-occurrence of diseases can be categorized in more 
than these two groups (figure 5). We have made a division between diathesis, direct 
comorbidity, indirect comorbidity and coexistence of diseases based on the mecha-
nism of association. The distinction between these groups is very fluid and not strict 
as new research will move diseases from one category to another. An example for this 
phenomenon is eosinophilic esophagitis. While previously known to be associated with 
atopic disorders, eosinophilic esophagitis has just recently been added to the atopic 
diathesis group.90 In a hypothetical example one could also imagine that a direct link 
could be found between fractures and atopic diseases mediated through osteoporosis 
due to vitamin-D deficiency.91 Fractures would then belong to the direct comorbidity 
group. Because of the aforementioned fluidity, choosing the right topics for new re-
search is impossible without regard of the previous scientific work. Of even more clinical 
importance and clinical relevance is the question whether the research into a particular 
comorbidity, be it direct or indirect, will lead to better outcomes or efficient disease pre-
vention programs. The research in the field of psoriasis and cardiovascular comorbidities 
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Figure 5. Categories of disease associations in atopy
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has shown that vast quantities of high quality peer reviewed papers do not necessarily 
translate into a change of clinical practice.85,92,93 Focus on the diseases from the atopic 
diathesis and direct comorbidity categories will likely have the highest yields in terms of 
advances in understanding of the pathogenetic mechanisms of atopy and implications 
for the daily clinical practice. Besides positive associations, atopy seems to be protective 
against Th-1 and Th-17 driven diseases. This is a phenomenon worth further investiga-
tion as this opens doors for a radically different concept in the treatment of immune 
disorders which is selective stimulation of the immune system instead of an immune 
system inhibition.
In conclusion, research into the comorbidities of atopy may be a very fruitful venture. 
Association does not automatically imply comorbidity. Atopy in itself is a systemic 
condition which by definition presents with multiple disorders making the patients and 
their treatment very complicated. Having additional comorbidities further increases the 
complexity of atopy cases. Fortunately, our research mainly provides evidence against 
an association with presumed comorbidities. We have shown that skin cancer is not a 
relevant comorbidity in AD. In addition atopy may actually confer protection against 
PSA and melanoma. The clinical relevance of the CHD-AD association needs further as-
sessment but does not seem to necessitate changes in practice. Future research should 
be based on previous methodologically sound epidemiologic research in harmony with 
findings from plausible and thoroughly researched fundamental scientific work.
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6
ENGLISH SUMMARy
Chapter 1 is the general introduction to this thesis. We discuss the concepts of atopy 
and comorbidity and how these are applied in the clinical and scientific fields. Both have 
been subject to change over time. There is a brief overview of the four atopic disorders, 
atopic dermatitis, food allergy, asthma and hay fever. The pathophysiology is discussed 
in depth with an emphasis on the epidermal barrier dysfunction and Th2-axis activation. 
This is used as a basis for the explanation of the comorbidity model of atopic dermatitis. 
This chapter also gives an overview of previously reported comorbidities of AD and the 
level of evidence for these reports. It reveals the multitude of categories of and indi-
vidual comorbidities of AD.
Chapter 2 contains the data from the studies in which have employed laboratory mea-
surements. In the first part we report the findings of our cross-sectional cohort study 
where the life time prevalences of atopic disorders and IgE-sensitization are compared 
between psoriasis vulgaris patients, psoriatic arthritis patients and controls. From this 
study it is clear that neither psoriasis vulgaris nor psoriatic arthritis are comorbidities 
of atopy. Moreover, atopy is less frequently found in psoriatic arthritis patients. These 
patients were 4 times less frequently affected by asthma and were half times as much 
sensitized to common aeroallergens. In addition the ones who were sensitized showed 
attenuated phenotypes of their disease. Second part of this chapter shows that patients 
with atopic dermatitis have decreased absolute levels of IgM-only B-memory cells. It is 
not clear what this means in terms of disease course or comorbidity.
Chapter 3 focuses on the skin malignancies and premalignancies as a comorbidity of 
atopy. In the first part we explore the possible pathomechanisms and evidence for this 
association. There is ample evidence that the epidermal barrier together with break-
down products of filaggrin minister to the protection against UV-radiation. Therefore, 
damage to this barrier may lead to UV-induced skin cancer. However this is not appli-
cable to community dwelling mild cases of AD as we have found in the second part 
of this chapter. There is no association between AD and actinic keratosis which are a 
prevalent premalignancie of the skin and a good marker of UV-induced DNA-damage. In 
the third part no positive association was found between AD and melanoma, the deadli-
est skin cancer. However our data suggest that asthma may confer protection against 
this malignancy.
Chapter 4 provides insight into the relationship between AD and cardiovascular disease 
(CVD). In this study nested within the Rotterdam Study cohort we have identified AD 
patients and compared them to controls in terms of CVD risk factors and coronary heart 
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disease prevalence. The Rotterdam Study has been specifically designed to address 
question concerning CVD. It contains high quality, validated and structurally verified 
data. We have found no association between AD and the traditional CVD risk factors. 
However AD was associated with coronary heart disease. Which seems to be an inde-
pendent relation.
Chapter 5 is the general discussion of the studies performed for this thesis and the 
literature of studies by others performed before or after the publication of these papers. 
It provides scientific and clinical context to our findings. We illustrate the links between 
atopy, cancer, autoinflammatory/immune disorders and cardiovascular disease. At the 
end we demonstrate how comorbidity research could account for various methodologi-
cal pitfalls and biases.
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NEdERLANdSE SAMENvATTING
Hoofdstuk 1 is de algemene introductietekst van dit proefschrift. Hierin worden de 
concepten “atopie” en “co-morbiditeit” besproken en de wijze waarop deze begrippen 
toegepast worden in het wetenschappelijke en het klinische veld. Beide termen zijn on-
derhevig geweest aan veranderingen van de tijdsgeest. We geven verder een overzicht 
van de vier klassieke atopische aandoeningen: atopisch eczeem, voedingsallergie, astma 
en hooikoorts. De pathofysiologie van atopie wordt uitgebreid besproken aan de hand 
van het model van epidermale barrieredysfunctie en Th2-as activatie. Dit model wordt 
ook gebruikt om de mogelijke co-morbiditeiten van atopische aandoeningen te verkla-
ren. Dit hoofdstuk maakt verder een opsomming van eerder co-morbiditeitsonderzoek 
en laat hier mee een veelvoud aan ziektebeelden zien.
Hoofdstuk 2 bevat de studies waarin de nadruk ligt op laboratoriumbepalingen. In het 
eerste gedeelte van dit hoofdstuk verslaan we de bevindingen van de cross-sectionele 
studie waarin we de prevalentie van atopische aandoeningen en IgE-sensibilisatie heb-
ben vergelijken tussen controles en patiënten met psoriasis vulgaris en artritis psoria-
tica. Deze studie wijst uit dat beide ziektebeelden geen co-morbiditeit zijn van atopie. 
Sterker nog, atopie wordt minder frequent gezien in patienten met artritis psoriatica. 
Deze patienten hadden een viervoudig verlaagde kans op astma en tweevoudig ver-
laagde kans op sensibilisatie door aeroallergenen. De gesensibiliseerde patienten had-
den zelfs milder verlopende artritis psoriatica. Het tweede deel laat zien dat patienten 
met atopisch eczeem verlaagde absolute aantallen IgM-only B-geheugencellen hebben. 
Het is niet duidelijk wat hiervan de betekenis is betreffende het ziektebeloop of co-
morbiditeitenlast.
Hoofdstuk 3 focust op huid(pre)maligniteiten als co-morbiditeiten van atopie. In het 
eerste deel verkennen we de mogelijke pathomechanismen en het bewijs voor de 
associaties. Er is voldoende bewijs dat de epidermale barrière samen met de afbraak-
producten van filaggrin meehelpen beschermen tegen Uv-straling. Wij concluderen dat 
schade aan deze barrière kan leiden tot Uv-geïnduceerde kanker. In deel twee blijkt dat 
dit mechanisme geen effect sorteert bij milde gevallen van atopisch eczeem binnen de 
gewone populatie. Er is geen associatie tussen actinische keratosen en atopisch eczeem. 
Actinische keratosen zijn een veelvoorkomende premaligniteit van de huid en een 
goede graadmeter van Uv-schade aan de huid. In het derde deel hebben we laten zien 
dat er geen positieve associatie is tussen atopisch eczeem en melanoom, de dodelijkste 
huidkanker. Niettemin lijkt het hebben van astma de kans op het melanoom te verlagen.
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Hoofdstuk 4 verschaft inzicht in de relatie tussen atopisch eczeem en cardiovasculair 
lijden. In deze studie, onderdeel van de Rotterdam Study cohort hebben we patienten 
met atopisch eczeem geïdentificeerd en vergeleken met controles voor wat betreft 
cardiovasculaire risicofactoren en coronaire hartziekten. De Rotterdam Study werd 
specifiek ontworpen met cardiovasculaire aandoeningen voor de ogen. Het verstrekt 
data van hoge kwaliteit die regelmatig gevalideerd en geverifieerd wordt. We hebben 
geen relatie gevonden tussen het atopisch eczeem en de traditionele cardivasculaire 
risicofactoren. Er was echter wel een associatie tussen atopisch eczeem en coronaire 
hartziekten. Dit lijkt een onafhankelijke relatie te zijn.
Hoofdstuk 5 bevat de algemene discussie van de verrichte studies en van de literatuur-
studie verricht voor dit proefschrift. Hierin pogen wij onze bevindingen in een bredere 
wetenschappelijke en klinische context te plaatsen. Mogelijke links tussen atopie en 
kanker, autoinflammatoire aandoeningen en cardiovasculaire aandoeningen worden 
besproken. Hier kaarten wij ook de methodologische valkuilen van co-morbiditeitson-
derzoek aan.
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ABBREvIATIONS
AD;    Atopic dermatitis
AK;    Actinic keratosis
AR;    Allergic rhinitis
BCC;    Basal cell carcinoma
CASPAR;   Classification Criteria for Psoriatic Arthritis
CHD;    Coronary heart disease
CI;    Confidence interval
CVD;    Cardiovascular disease
DAS 28;    Disease Activity Score 28
HAQDI;    Health assessment questionaire-disability index
HAQ-VAS;   Health assessment questionnaire visual analogue scale
IRR;    Incidence rate ratio
KC;    Keratinocyte cancer
OR;    odds ratio
PASI;    Psoriasis Area and Severity Index
PSO;    Psoriasis vulgaris or chronic plaque type psoriasis
PSA;    Psoriatic arthritis
RA;    Rheumatoid arthritis
RS;    Rotterdam study
SCC;    Squamous cell carcinoma
SD;    Standard deviation
Th;    T-helper cell
UVB;    Ultraviolet-B
UVR;    Ultraviolet radiation
95% CI;    95% confidence interval
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De indirecte betrokkenheid van mijn vrienden heeft minstens evenveel bijgedragen 
aan het voltooien van dit proefschrift. Ik ben omringd door psychiaters en begin daar 
langzamerhand conclusies uit te trekken….
Aram, jij en ik begrijpen elkaar op het meest basale niveau. Ooit zullen de wetenschap-
pers een gen ontdekken waardoor dit komt. Ik gok dat dit gen op het Y-chromosoom zal 
liggen. Ik ben blij jou aan mijn zijde te hebben mocht het Wilde Westen ooit herleven.
Nabil, als je toch de wereld zo nodig wil verbeteren begin dan alsjeblieft bij mij. Samen 
zullen wij blijven vechten tegen levensongemakken en stress.
Dinesh, jouw professionaliteit en onafhankelijkheid in zowel leven als beroep zie ik als 
voorbeeld. Ik ben nog altijd onder de indruk van jouw loyaliteit en onbevangenheid.
Femke en Lauke, het is leuk om te zien hoeveel gelijkenis de levensloop van onze 
gezinnen vertoont (van werkomstandigheden en kinderen tot eilandvakanties en hui-
zenjacht). Jullie zijn altijd een oase van vriendschap en gezelligheid. Dat wordt straks 
een vakantie in optima forma op Texel!
Mijn schoonouders, Kees en Cocky de Vos, bieden, samen met Irene en Joshua, een 
ideale uitvalsbasis voor uitjes met kinderen. Zij het bij jullie thuis of op Texel. Dit helpt 
ons gezinnetje bijtanken. De rest van de schoonfamilie wil ik ook bedanken voor alle 
leuke uitjes, feestjes en vakanties.
In het bijzonder mijn zwager, Kees den Braber, die ik waardeer om zijn BBQ-skills en 
zijn opvoedkundige technieken. Kees, jij maakt familie-uitjes plezant voor maag en 
cerebrum.
En mijn schoonbroer Alexander, die altijd voor iedereen klaarstaat. Zo ook voor mij en 
mijn gezin. Mensen als jij maken het leven leefbaar, Alex.
Mijn oom Alija Kapidzic en zijn vrouw en kinderen Bahira, Adnan en Atija wil ik bedanken voor 
“de oversteek”. Een zeer cruciale stap, die mijn hele huidige leven mogelijk heeft gemaakt.
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Het zijn de kleine dingen, daden en woorden waarmee we elkaar beïnvloeden en helpen 
te worden wat we zijn. Tijdens de kinderjaren is het effect hiervan het grootst. Ik moet 
pas vijf jaar oud zijn geweest toen ik ze hoorde, maar de woorden van mijn opa Husejn 
resoneren nog in mijn hoofd: ‘Kloni se neobrazovanog insana.’ Zijn geloof in onderwijs, 
redelijkheid en nuchterheid was onmetelijk. In andere omstandigheden had hij het 
waarschijnlijk geschopt tot goeroe, adviseur aan het hof of internationaal filosoof. Ik ken 
hem als de beste opa van de wereld.
Mijn ouders, Rizah en Hanumica, en mijn broer, Dino, zijn verantwoordelijk voor het 
ontstaan van een gezinsmilieu waarin de visie en volharding om een proefschrift te 
schrijven, hebben kunnen ontstaan. Mijn vader, idealist, liefhebber van intellectualisme 
en mijn moeder, overlever en pragmatische probleemoplosser, zijn uiteraard biologisch 
en sociaal verantwoordelijk voor wie ik ben en wat ik heb kunnen bereiken. Veel dank 
voor de grote offers die jullie hebben gebracht, zodat ik mij heb kunnen ontwikkelen.
In mijn jonge jaren heb ik mij kunnen spiegelen aan Dino. Jij bent het beste wat Bosnië 
heeft voortgebracht sinds cevapcici. Je bent een man van je woord, een vijand der 
hypocrieten en ik ben er trots op dat je mijn breur bent! Nikki, aan jou durf ik hem wel 
toe te vertrouwen.
Als laatste wil ik mijn vrouw en mijn dochters bedanken. De tijd gespendeerd aan mijn 
promotie ging af van onze tijd samen. Bedankt voor jullie geduld.
Anneke, bedankt voor het meehelpen ontwerpen van de omslag. Ik bewonder je cre-
ativiteit, je morele kompas en je rechtvaardigheidsgevoel. Als perfectionist sta je soms 
lijnrecht tegenover deze afraffelaar, maar je bent altijd bereid tijd in mij te steken. Alles 
zou betekenisloos zijn als ik niet op jouw liefde kon rekenen, Anneke. Jij staat centraal in 
mijn leven. Ik ken alleen nog niet alle manieren om dat te laten blijken, maar daar ga ik 
zeker nog intensiever aan werken.
Lieve Nora en Iza, alles wat ik ooit heb bereikt, valt in het niet en verbleekt bij jullie, al 
hebben jullie daar nu geen enkel idee van. Ik wil heel graag de beste vader voor jullie 
zijn, ongeacht de omstandigheden en ik zal daar nog meer mijn best voor doen. Ik houd 
heel veel van jullie drie!
Enes

De volgende bedrijven hebben een financiële bijdrage geleverd voor de drukkosten van 
dit proefschrift.
Allergopharma
Celgene
Eurocept
Leopharma
Pfizer
Pierre Fabre Avene
Fagron
Medi Nederland
Medi Zorg
Oldekamp
Galderma
D M Diagnostica
